Productivity Costs Associated with Cardiometabolic Risk Factor Clusters in the United States
Quality of Life Related to Oral versus Subcutaneous Iron Chelation
Development and Validation of the Congestion Quantifier Seven-Item Test (CQ7)
Development and Validation of a New Spanish Instrument to Measure Health-Related Quality of Life in Patients with Allergic Rhinitis
Performance Comparison of Likert and Binary Formats of SF-36 Version 1.6 Across ECRHS II Adults Populations
Development, Validation, and Application of a Microsimulation Model to Predict Stroke and Mortality in Medically Managed Asymptomatic Patients with Significant Carotid Artery Stenosis
Methods for Integrating Medication Compliance and Persistence in Pharmacoeconomic Evaluations
International Price Comparisons for Novel and Follow-on Drugs
International Price Comparisons for Novel and Follow-on Drugs
Prices for Innovative Pharmaceutical Products That Provide Health Gain
REVIEWER ACKNOWLEDGMENT
POST-AMI DRUG THERAPY PERSISTENCE AND RISK OF REINFARCTION IN A MEDICAID POPULATION
COST-EFFECTIVENESS OF ROSUVASTATIN VERSUS ATORVASTATIN, SIMVASTATIN, AND PRAVASTATIN FROM A CANADIAN HEALTH CARE PERSPECTIVE
DO DIFFERENCES IN DOSE IMPACT ADHERENCE TO SINGLE-PILL AMLODIPINE/ATORVASTATIN VERSUS 2-PILL AMLODIPINE AND ATORVASTATIN?
BENEFIT/RISK OF IRBESARTAN/HYDROCHLOROTHIAZIDE AS FIRST-LINE TREATMENT OF SEVERE HYPERTENSION
COST-EFFECTIVENESS OF INSULIN DETEMIRVERSUS NPH FOR TYPE 1 DIABETES PATIENTS IN A GERMAN SETTING. A MODELING EVALUATION BASED UPON RESULTS FROM A META-ANALYSIS
LONG-TERM COST-UTILITY ANALYSIS OF INSULIN ASPART (NOVORAPID®) VERSUS HUMAN SOLUBLE INSULIN IN TYPE 2 DIABETES PATIENTS IN THE GERMAN SETTING
DIFFERENCES IN HEALTH RELATED RESOURCE USE IN THE 6 MONTHS PRIOR TO AND AFTER INSULIN INITIATION IN PATIENTS WITH TYPE 2 DIABETES IN GERMANY AND UNITED KINGDOM
THE RELATIVE COST EFFECTIVENESS OF SWITCHING TO INSULIN GLARGINEVERSUS NPH INSULIN IN INSULIN NAIVE AND NON INSULIN NAIVE TYPE 2 DIABETES PATIENTS USING UK REAL LIFE DATA
ASSESSING THE GENERALISABILITY OF COST EVALUATION RESULTS USING THE EUCLIDEAN METRIC AND PRINCIPAL COMPONENTS ANALYSIS
BAYESIAN MODELING OF RESOURCE USE ALONGSIDE MULTINATIONAL RANDOMISED CLINICAL TRIALS
THE DEVELOPMENT OF AN INCREMENTAL WILLINGNESS TO PAY CURVE DERIVED FROM A DISCRETE CHOICE EXPERIMENT
COMPARISON OF THREE INSTRUMENTS ASSESSING THE QUALITY OF ECONOMIC EVALUATIONS
RECOMPUTING VALUES FOR EQ-5D IN ACCORDANCE WITH NICE APPRAISAL GUIDANCE
NON-PERSISTENT USE OF ORAL ANTIDIABETIC DRUGS LEADS TO 20% DECREASED CHANCE OF HBA1C GOAL-ATTAINMENT IN DAILY CLINICAL PRACTICE
PATIENTS', PARENTS', AND PHYSICIANS' RISK-BENEFIT TRADE-OFF PREFERENCES FOR CROHN'S DISEASE TREATMENTS
BACK PAIN IN GERMANY
USING THE FACT-NEUROTOXICITYTO EVALUATE QUALITY OF LIFE IN CANCER PATIENTS FROM ACROSS THE GLOBE
DEVELOPMENT AND VALIDATION OF OPTIMALLY WEIGHTED MEASURES OF GLOBAL HEALTH-RELATED QUALITY OF LIFE (QOL)AND UTILITY BASED ON A CANCER-SPECIFIC QOL INSTRUMENT
EFFECTIVENESS OF EPOETIN ALPHA VERSUS DARBEPOETIN IN CHEMOTHERAPY-INDUCED ANAEMIA IN THE GERMAN SETTING
COST-EFFECTIVENESS OF PEGYLATED LIPISOMAL DOXORUBICIN VS. CONVENTIONAL DOXORUBICIN IN AVOIDANCE OF CARDIOTOXICITY FOR METASTATIC BREAST CANCER IN THE FIRST TREATMENT YEAR
INCREMENTAL DIFFERENCES IN RESOURCE UTILIZATION AND COSTS OF TREATING PERSONS INFECTED WITH HIV IN A LOW SOCIOECONOMIC NEIGHBORHOOD
COST-EFFECTIVENESS AND COST-UTILITY OF RITUXIMAB MAINTENANCE THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA IN FRENCH SETTING
ES3
ES4/PSU2
VALIDATION OF POMS QUESTIONNAIRE IN POSTMENOPAUSAL WOMEN
PATIENT CHARACTERISTICS IMPACTING QUALITY OF LIFE (EQ-5D) OF FEMALES WITH STRESS URINARY INCONTINENCE SYMPTOMS
PATIENT'S PREFERENCES FOR OSTEOPOROSIS DRUG TREATMENT
EVALUATION OF IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE USING ORAL MESALAZINE ALONE OR IN COMBINATION WITH A MESALAZINE ENEMA INACTIVE ULCERATIVE COLITIS
COST-EFFECTIVENESS OF CYCLOOXYGENASE-2 INHIBITOR PARECOXIB COMPARED TO OPIOIDS AFTER NONCARDIAC SURGERY IN THE UNITED KINGDOM
MICRO-COSTING OF SURGICAL PROCEDURES RELATED TO INTRACEREBRAL HAEMORRHAGE IN A UK HEALTH CARE SETTING
NINEYEAR FOLLOW UP OF BIRMINGHAM HIP RESURFACING IN CONTEXT OF SURVIVAL AND COMPLICATIONS
THE COST-EFFECTIVENESS OF TITANIUM CAGE VERSUS FEMORAL RING ALLOGRAFT IN CIRCUMFERENTIAL LUMBAR FUSION
IMPACT OF ROSIGLITAZONE THERAPY ON THE LIPID PROFILE AND LIPID-LOWERING TREATMENT IN TYPE 2 DIABETES PATIENTS
COMPARING BRITISH AND GERMAN DIABETES GUIDANCE WITH RESPECT TO LONGTERM OUTCOMES AND ASSOCIATED COSTS
CLINICAL AND PATIENT REPORTED OUTCOMES OVERTHE FIRST 6 MONTHS OF INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES IN GERMANY AND THE UNITED KINGDOM
TREATMENT ADHERENCE AND BARRIERS TO ADHERENCE ARE ASSOCIATED WITH GLYCEMIC CONTROL AND EXPERIENCE OF HYPOGLYCEMIA AMONG PATIENTS WITH TYPE-2 DIABETES MELLITUS (T2DM) ON ORAL ANTI-HYPERGLYCEMIC AGENTS (OHA) IN EUROPE
RESOURCE USE AND COST OF DIAGNOSTIC WORKUP OF WOMEN WITH SUSPECTED BREAST CANCER
AN ECONOMIC EVALUATION OF DASATINIB AS A TREATMENT FOR CHRONIC PHASE CHRONIC MYELOID LEUKAEMIA IN SCOTLAND
COST-MINIMIZATION ANALYSIS OF CAPECITABINE + OXALIPLATIN (XELOX)VS. INFUSIONAL 5-FU/LV + OXALIPLATIN (FOLFOX-6)AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) IN THE FRENCH SETTING
PHARMACOECONOMIC ANALYSIS OF ERLOTINIB COMPARED WITH DOCETAXEL FOR THE TREATMENT OF RELAPSED NON-SMALL-CELL LUNG CANCER (NSCLC) IN TURKEY
HEALTH SYSTEM CORRELATES OF RECEIPT OF RADIATION AFTER BREAST CONSERVING SURGERY IN LOW-INCOME MEDICAID-ENROLLED WOMEN
ASSOCIATIONS BETWEEN NEGATIVE SYMPTOMS, SERVICE USE, AND COSTS FOR PATIENTS WITH SCHIZOPHRENIA IN FIVE EUROPEAN COUNTRIES
ASSESSING THE IMPACT OF A NATIONAL DRUG BENEFIT PROGRAM ON THE USE OF GENERIC DRUGS AND DIFFERENT THERAPEUTIC CLASSES
PROMOTING A DRUG'S HEALTH ECONOMIC ADVANTAGES IN MEDICAL JOURNAL ADVERTISING IN THE U.S.
IMPACT OF ANTI-TUMOR NECROSIS FACTORS ON HEALTH CARE RESOURCE UTILIZATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES
ECONOMIC CONSEQUENCES OF PROVIDING RITUXIMAB AS A TREATMENT ALTERNATIVE FOR RHEUMATOID ARTHRITIS IN THE NETHERLANDS
CHANGES IN BODYWEIGHT AND ASSOCIATED DOSING REQUIREMENTS FOR RHEUMATOID ARTHRITIS PATIENTS RECEIVING INFLIXIMAB---RESULTS FROM ANALYSIS OF THE BRITISH SOCETY FOR RHEUMATOLOGY'S BIOLOGICS REGISTER (BSRBR)
COST-EFFECTIVENESS OF BONE DENSITOMETRY SCREENING COMBINED WITH ALENDRONATE THERAPY FORTHOSE WHO HAVE OSTEOPOROSIS
FONDAPARINUX (FOND) VERSUS ENOXAPARIN (ENOX) FOR PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLIC EVENTS (VTE) IN PATIENTS UNDERGOING MAJOR ORTHOPEDIC SURGERY OF THE LOWER LIMBS (MOSLL) IN GERMANY
SIROLIMUS-ELUTING VERSUS BARE-METAL CORONARY STENTS
COMPARISON OF THE COST-EFFECTIVENESS OF SEROLIMUS-ELUTING VERSUS BARE-METAL STENTS IN RELATION TO PATIENT CORONARY ARTERY DISEASE STATUS
THE COST-EFFECTIVENESS (COST-UTILITY) OF EPROSARTAN IN HYPERTENSIVE PATIENTS WITH CEREBROVASCULAR DISEASE IN BELGIUM, GERMANY, SPAIN, UNITED KINGDOM, AND SWEDEN
DOES ARTHROSCOPIC ACROMIOPLASTY PROVIDE ANY ADDITIONAL VALUE IN THE TREATMENT OF SHOULDER IMPINGEMENT SYNDROME? A TWO-YEAR RANDOMIZED CONTROLLED TRIAL
COST COMPARISON BETWEEN HAEMODIALYSIS AND PERITONEAL DIALYSIS IN NORWAY FOR PATIENTS WHO CAN USE EITHER TREATMENT MODALITY
ASSESSMENT OF LONG-RUN ECONOMIC BENEFITS ASSOCIATED WITH IN-VITRO FERTILIZATION (IVF) FUNDING DECISIONS
COST-EFFECTIVENESS OF DARUNAVIR/R IN HIGHLY TREATMENT-EXPERIENCED HIV/AIDS PATIENTS IN DIFFERENT EUROPEAN HEALTH CARE SETTINGS
COST-EFFECTIVENESS OF INTRATHECAL BACLOFEN THERAPY VERSUS CURRENT THERAPIES IN DISABLED SPASTICITY
MODELING THE COST-EFFECTIVENESS OF A NEW TREATMENT FOR MS (NATALIZUMAB) COMPARED TO CURRENT STANDARD PRACTICE IN SWEDEN
MODELING TREATING MULTIPLE SCLEROSIS WITH DISEASE MODIFYING DRUGS USING DISCRETE EVENT SIMULATION
COST-EFFECTIVENESS OF A LIDOCAINE PLASTER RELATIVE TO PREGABALIN IN THE TREATMENT OF POST-HERPETIC NEURALGIA IN SCOTLAND
A RETROSPECTIVE, OBSERVATIONAL STUDY COMPARING OUTCOMES OF ASTHMA TREATMENT WITH FIXED COMBINATIONS OF INHALED CORTICOSTEROID AND LONG-ACTING â2-AGONIST (ICS/LABA) IN REAL-LIFE PRACTICE
RESOURCE USE AND FINANCIAL IMPACT OF CRITICALLY ILL PATIENTS WITH PNEUMONIA AND RESPIRATORY FAILURE IN THE UNITED STATES
IMPACT OF SOCIO-ECONOMIC FACTORS ON PATIENTS' KNOWLEDGE OF THEIR CONDITION, INVOLVEMENT IN TREATMENT DECISIONS AND THE SUBSEQUENT COMPLIANCE WITH THEIRTREATMENT REGIMEN
ASTHMA COSTS AND UTILIZATION IN A MANAGED CARE ORGANIZATION
GLUCOSAMINEVS PLACEBO IN THE TREATMENT OF OSTEOARTHRITIS
DOES RACE INFLUENCE A PATIENT'S LIKELIHOOD OF BEING PRESCRIBED SELECTIVE CYCLOOXYGENASE-2 INHIBITORS (COX-2S) VERSUS OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (NSAIDS) IN MEDICAID MANAGED CARE PLANS (MCOS)?
COST-BENEFIT OF RITUXIMAB FOR RHEUMATOID ARTHRITIS PATIENTS IN ARGENTINA
ASSOCIATION BETWEEN SWITCHING PATTERNS AMONG ANTI-TUMOR NECROSIS FACTORS (ANTI-TNFS) AND HEALTH CARE COSTS IN THE TREATMENT OF RHEUMATOID ARTHRITIS
ADALIMUMAB, ETANERCEPT OR INFLIXIMAB
A COST EFFECTIVENESS PRELIMINARY STUDY ON A NEW TOTAL KNEE ARTHROPLASTY SYSTEM AND A PERIPHERAL NERVE BLOCKADETECHNIQUE
COST EFFECTIVENESS OF AUTOANTIBODIES AGAINST CYCLIC CITRULLINATED PEPTIDE IN THE VERY EARLY DIAGNOSIS OF RHEUMATOID ARTHRITIS
LEFLUNOMID VERSUS CYCLOSPORIN IN METHOTREXATE-RESISTANT RHEUMATOID ARTHRITIS IN POLAND
A SYSTEMATIC REVIEW OF COST-EFFECTIVENESS ANALYSES OF BIOLOGICAL DMARDS IN RHEUMATOID ARTHRITIS
COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF ANTI-TNF-A DRUGS IN PSORIATIC ARTHRITIS
COST-EFFECTIVENESS OF ADDING LEFLUNOMIDE TO STANDARD DRUG SEQUENCES FOR RHEUMATOID ARTHRITIS PATIENTS IN POLAND
FINANCIAL CONSEQUENCES OF THERAPEUTIC STRATEGIES IN OSTEOARTHRITISTREATMENT IN CZECH REPUBLIC
ANNUAL TREATMENT COSTS OF PATIENTS WITH RHEUMATOID ARTHRITIS WITH METOTREXATE AND LEFLUNOMIDE IN SPAIN
COST MINIMIZATION ANALYSIS OF RITUXIMAB VERSUS INFLIXIMAB, ADALIMUMAB AND ETANERCEPT FOR RHEUMATOID ARTHRITIS FROM A PAYER PERSPECTIVE IN BRAZIL
IMPACT OF CO-MORBIDITY BURDEN ON REAL WORLD HEALTH CARE COSTS IN RHEUMATOID ARTHRITIS PATIENTS INITIATING ANTI-TUMOR NECROSIS FACTORTHERAPY
COST OFANKYLOSING SPONDYLITIS IN CZECH REPUBLIC—DIRECT AND INDIRECT COSTS
A SYSTEMATIC REVIEW OF THE GLOBAL COST-OF-ILLNESS OF RHEUMATOID ARTHRITIS
HIDDEN COST OF RHEUMATOID ARTHRITIS
COMPARISON OF ORAL LEFLUNOMIDE AND METOTREXATE SC FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
ASSOCIATION BETWEEN DOSE CHANGES AND HEALTH CARE COSTS IN RHEUMATOID ARTHRITIS PATIENTS WHO RECEIVED INFLIXIMABTHERAPY
IMPACT OF ANTI-TUMOR NECROSIS FACTORS ON HEALTH CARE COSTS IN PATIENTS WITH RHEUMATOID ARTHRITIS
COST-EFFECTIVENESS OF RITUXIMAB (MABTHERA) COMPARED WITH ABATACEPT (ORENCIA) FORTHE TREATMENT OF MODERATE/SEVERE RHEUMATOID ARTHRITIS (RA) IN THE UNITED KINGDOM
COST-UTILITY OF ABATACEPT, A NEW BIOLOGIC TREATMENT FOR PATIENTS WITH RHEUMATOID ARTHRITIS WHO FAILED ANTI-TNF THERAPY
COST-UTILITY ANALYSIS OF RITUXIMAB TREATMENT IN RHEUMATOID ARTHRITIS AFTER ANTI-TNF-ALFATHERAPY IN HUNGARY
ASSOCIATION OF PERSISTENCE WITH ANTI-TUMOR NECROSIS FACTOR (ANTI-TNF) THERAPY AND HEALTH CARE COSTS IN PATIENTS WITH PSORIATIC ARTHRITIS
THE UNINTENDED CONSEQUENCES OF WITHDRAWING DRUGS FROM THE MARKET
WITHDRAWAL OF ROFECOXIB FROM THE MARKET; THERAPEUTIC AND ECONOMIC IMPLICATION FOR THE NETHERLANDS
GEOGRAPHICAL VARIATION OF PHARMACOLOGICAL PRESCRIPTION WITH BAYESIAN HIERARCHICAL MODELS
AZATHIOPURINE, TPMT POLYMORPHISMS AND ADRS
SWITCHING PATTERNS AMONG ANTI-TUMOR NECROSIS FACTORS (ANTI-TNFS) IN THE TREATMENT OF RHEUMATOID ARTHRITIS
MULTILEVEL ANALYSIS
INVESTIGATION OF RESPONSE SHIFT IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS UNDERGOING TOTAL KNEE REPLACEMENT
OSWESTRY HIP SCORE
GLYCEMIC CONTROL GOAL ATTAINMENT AMONG TYPE 2 DIABETIC PATIENTS WHO INITIATED ORAL COMBINATION THERAPY IN HUNGARY
A PHARMACOECONOMIC EVALUATION FOR DIABETES TYPE 2 (DM 2) PATIENTS WITH INHIBITORS OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ANDTHIAZOLIDINEDIONES (TZD)AS ADD-ON THERAPY
COMPARING EFFICIENCY OF INSULIN GLARGINE VS. NPH INSULIN IN PATIENTS WITH TYPE 2 DIABETES
A PHARMACOECONOMIC EVALUATION FOR DIABETES TYPE 2 (DM 2) WITH INHIBITORS OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ANDTHIAZOLIDINEDIONES (TZD) IN MONOTHERAPY
GLYCAEMIC AND WEIGHT EFFECTS OF EXENATIDE FOR DIFFERENT AGE GROUPS
DATABASE ASSESSMENT OF THE EFFECTIVENESS OF BRAND VERSUS GENERIC ROSIGLITAZONE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
ADDITION OF INHALED HUMAN INSULIN AS AN OPTION FOR PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON ORAL ANTIDIABETICS SHOULD AVOID COMPLICATIONS PREDICTED BY EAGLE MODEL
EVALUATION OF THE ASSOCIATION BETWEEN GLUCOSE VARIABILITY, AS MEASURED BY THE DIFFERENCE BETWEEN MAXIMUM AND MINIMUM, INTERMITTENT, RANDOM BLOOD GLUCOSE OBSERVATIONS, AND LONG TERM CLINICAL OUTCOME IN SUBJECTS WITH TYPE 2 DIABETES TREATED WITH INSULIN
INDIRECT COMPARISON OF ONCE DAILY INSULIN DETEMIR AND GLARGINE IN REDUCING WEIGHT GAIN AND ACHIEVING GLYCEMIC CONTROL, WHEN ADMINISTERED IN ADDITION TO CONVENTIONAL ORAL ANTIDIABETIC THERAPY IN THE TREATMENT OF TYPE 2 DIABETES PATIENTS; A META-ANALYSIS
UNDERSTANDING INSULIN THERAPY INITIATION FROM A PRIMARY CARE PERSPECTIVE IN THE UNITED KINGDOM USING LOCAL DATA
ASSOCIATION BETWEEN TOPICAL CORTICOSTEROID USE AND DIABETES ONSET
ROSIGLITAZONE IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES
THE COST OF THE INEFFICIENCY IN DIABETES IN HEALTH PRIMARY CARE
2-YEAR GLYCEMIC CONTROL FOLLOWING INITIATION OF INSULIN GLARGINEVERSUS NPH INSULIN IN INDIVIDUALS WITH TYPE 2 DIABETES (T2DM)
LOWER RATE OF HOSPITALIZATION IN SUBSEQUENT YEAR OF INSULIN GLARGINE VS NPH INITIATION IN INDIVIDUALS WITH TYPE 2 DIABETES (T2DM)
GLYCEMIC CONTROL WITH INSULIN GLARGINE PLUS GLULISINE VERSUS PREMIX IN REAL WORLD PRACTICES—A RANDOMIZED, PROSPECTIVE, OBSERVATIONAL STUDY
MEDICAL COSTS AMONG INDIVIDUALS WITH DIABETES, HYPERTENSION OR HYPERCHOLESTEROLEMIA
THE COST-EFFECTIVENESS OF PIOGLITAZONE COMPARED WITH ROSIGLITAZONE
THE COST-EFFECTIVENESS OF PIOGLITAZONE COMPARED WITH SITAGLIPTIN
COST-EFFECTIVENESS OF INSULIN DETEMIRVERSUS NPH FOR TYPE 1 DIABETES PATIENTS IN AN ITALIAN SETTING. A META-ANALYSIS
COST-EFFECTIVENESS OF STRICT “GET TO GOAL” TREATMENT DIRECTIVES IN THE TREATMENT OF YOUNGER PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS (T2DM)
EVALUATING THE LONG-TERM COST-EFFECTIVENESS OF INSULIN ASPART (NOVORAPID®) VERSUS HUMAN SOLUBLE INSULIN IN PATIENTS WITH TYPE 2 DIABETES IN SPAIN AND ITALY
COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 VERSUS HUMAN PREMIX INSULIN FORTYPE 2 DIABETES PATIENTS IN A POLISH SETTING
A PHARMACOECONOMIC COMPARISON BETWEEN ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN PATIENTS WITH DIABETIC NEPHROPATHY
COST-EFFECTIVENESS OF DETEMIRVERSUS NPH FOR TYPE I DIABETES PATIENTS TREATED WITH BASAL-BOLUS THERAPY IN A BELGIUM SETTING. A MODELING EVALUATION BASED ON RESULTS FROM A META-ANALYSIS OF THREE CLINICAL TRIALS
COSTS AND NEONATAL OUTCOMES AFTER INSULIN ASPART COMPARED WITH HUMAN INSULIN IN PREGNANT WOMEN WITH TYPE 1 DIABETES
COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 VERSUS HUMAN PREMIX INSULIN FORTYPE 2 DIABETES PATIENTS IN CHINA
COST-EFFECTIVENESS ANALYSIS OF ACARBOSE IN THE PREVENTION OF TYPE 2 DIABETES IN SOUTH KOREA
THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN USING UK REAL LIFE DATA IN TYPE 1 DIABETES MELLITUS AND THE COMBINED EFFECT OF HBA1C AND HYPOGLYCAEMIA REDUCTION
EVALUATING THE COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 VERSUS HUMAN PREMIX INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES IN A SPANISH SETTING
TOTAL COST REDUCTION IN TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS TREATED WITH PIOGLITAZONE (PIO) BASED THERAPIES VERSUS NON-THIAZOLIDINEDIONE (NON-TZD) BASED THERAPIES
EVALUATING THE LONG-TERM CLINICAL AND ECONOMIC IMPLICATIONS OF CONVERTING TYPE 2 DIABETES PATIENTS TO INSULIN DETEMIR (± ORAL HYPOGLYCEMIC AGENTS) FROM INSULIN GLARGINE BASED REGIMENS IN GERMANY; DATA FROM THE PREDICTIVE STUDY
COST EFFECTIVENESS OF JANUVIA VERSUS AVANDIA AS SUPPLEMENTARY TREATMENT IN COMBINATION WITH METFORMIN FOR PATIENTS WITH TYPE 2 DIABETES
LONG-TERM COST-EFFECTIVENESS ANALYSIS OF A MODERN INSULIN IN PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES IN THE GERMAN SETTING; DATA FROM THE PREDICTIVE STUDY
ECONOMIC ANALYSIS OF THE TREATMENT WITH INSULIN GLARGINE PLUS ORAL ANTIDIABETICS (BOT) COMPARED TO TWICE DAILY PREMIXED INSULIN (CT) BASED ON THE LAPTOP TRIAL
INSULIN USE AND COSTS OF CARDIOVASCULAR DISEASE EVENTS (CVD) AMONG PATIENTS WITH TYPE 2 DIABETES
MEALTIME INSULIN ASPART REDUCES THE LONG-TERM COST OF COMPLICATIONS COMPARED TO HUMAN INSULIN AS PART OF BASAL-BOLUS THERAPY IN POLISH TYPE 2 DIABETES PATIENTS
COST OF ILLNESS STUDY OF TYPE-2 DIABETES IN COLOMBIA
IMPACT OF HBA1C IN TYPE 2 DIABETES MELLITUS IN MEXICO
SIMULATION OF LONG-TERM COSTS OF COMPLICATIONS IN TYPE II DIABETES IN THE UNITED STATES
INSULIN AND INSULIN ANCILLARY USAGE, THE ANNUAL COST OF TREATING TYPE 2 DIABETES WITH INSULIN IN THE UNITED KINGDOM
COSTS ASSOCIATED WITH THE FIRST SIX MONTHS OF INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES IN GERMANY ANDTHE UNITED KINGDOM
COMPARATIVE STUDY OF ANNUAL TREATMENT COSTS OF GLARGINE INSULIN AND DETEMIR INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SPAIN
INPATIENT COSTS AND HEALTH OUTCOMES FOR PREGNANT WOMEN WITH TYPE 1 DIABETES
THE RELATIONSHIP BETWEEN GLYCEMIC CONTROL AND DIABETES-RELATED COSTS
COST-UTILITY OF INSULIN DETEMIR VERSUS NPH FOR TYPE I DIABETES PATIENTS TREATED WITH BASAL-BOLUS THERAPY IN A FRENCH SETTING. A MODELING EVALUATION BASED ON RESULTS FROM A META-ANALYSIS OF THREE CLINICAL TRIALS
LONG-TERM ECONOMIC OUTCOMES ASSOCIATED WITH INSULIN ASPART VERSUS HUMAN BOLUS INSULIN IN TYPE 2 DIABETES PATIENTS IN THE SWEDISH SETTING
A RETROSPECTIVE ANALYSE OF THE IMPACT OF INCREASING BODY MASS INDEX ON MEDICAL RESOURCES FOR PEOPLE WITH TYPE 2 DIABETES IN UNITED STATES
ESTIMATE OF HEALTH CARE RESOURCES NEEDED TO INITIATE INSULIN—RELATIVE COSTS OF DIFFERENT OPTIONS IN UK CLINICAL PRACTICE
UTILIZING OF CLAIMS DATABASES FOR IMPROVEMENT OF PRESCRIPTION HABITS FOR DIABETES MELLITUSTYPE 2
DRUG USE FOR DIABETES MELLITUSTYPE 2 AND ITS COMPLICATIONS IN SLOVAKIA
FACTORS ASSOCIATED WITH THE CHOICE OF A GLITAZONES OR SULFONYLUREA AS ADD ON TO ONGOING METFORMIN MONOTHERAPY
AN EVALUATION OF TREATMENT DISCONTINUATION PATTERNS IN PEOPLE WITH TYPE 1 AND TYPE 2 DIABETES SWITCHED TO ALTERNATIVE SHORT ACTING INSULIN REGIMENS IN UK GENERAL PRACTICE
FACTORS ASSOCIATED WITH CONTINUED CLINICAL INERTIA AMONG PATIENTS WITH TYPE 2 DIABETES
IMPACT ON HEALTH CARE COST OF INCREASING BODY MASS INDEX FOR PEOPLE WITH TYPE 2 DIABETES—A CROSS SECTIONAL STUDY IN UNITED STATES
FACTORS RELATED TO CSII USE AND REASONS FOR DISCONTINUATION
ADMINISTRATIVE CLAIMS ANALYSIS OF NEW EXENATIDE PATIENTS WITH TYPE 2 DIABETES
CHANGES IN CONCOMITANT DIABETES THERAPIES ASSOCIATED WITH THE INITIATION OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES
METHODOLOGICAL APPROACH ASSESSING AN ASSOCIATION OF THE SURROGATE PARAMETER BETA-CELL ACTIVITY AND PATIENT-RELEVANT OUTCOMES IN TYPE 2 DIABETIC PATIENTS
ASSOCIATION OF INADEQUATE METABOLIC CONTROL AND CO-MORBIDITIES AND HEALTH RESOURCE UTILIZATION IN PATIENTS WITH DIABETES MELLITUS IN A SPANISH POPULATION
VALIDATING THE EXTERNAL VALIDITY OF RANDOMIZED CONTROLLED TRAILS WITH OBSERVATIONAL STUDIES AND CAUSAL EFFECT METHODS (PROPENSITY SCORE, MARGINAL STRUCTURE MODEL AND DOUBLY ROBUST METHODS)
LONG-TERM CLINICAL OUTCOMES OF INSULIN DETEMIR VERSUS NPH FORTYPE I DIABETES PATIENTS IN SPAIN
ESTIMATING THE LONG-TERM CLINICAL OUTCOMES ASSOCIATED WITH SWITCHING TO INSULIN ASPART (NOVORAPID®) FROM HUMAN SOLUBLE INSULIN IN TYPE 2 DIABETES PATIENTS IN THE POLISH SETTING
PDB64
THE PROSIT DISEASE MODELLING COMMUNITY—OPEN SOURCE DEVELOPMENT OF DECISION ANALYTIC DISEASE MODELS FOR TYPE 2 DIABETES
RETROSPECTIVE COMPARISON OF COMPLIANCE TO FIXED-DOSE COMBINATION VERSUS SINGLE AGENT COMBINATION THERAPY FOR THE TREATMENT OF DIABETES
PERSISTENCE PATTERNS WITH ORAL ANTI-HYPERGLYCEMIC DRUG TREATMENT IN NEWLYTREATED PATIENTS— A POPULATION-BASED STUDY
ISA MEASUREMENT-GUIDED INTERVENTION PROGRAM TO LENGTHEN PERSISTENCE WITH METFORMIN MONOTHERAPY COST EFFECTIVE IN TYPE 2 DIABETES?
DETERMINANTS OF STOPPING TREATMENT WITH ORAL ANTIDIABETIC DRUGS IN DAILY CLINICAL PRACTICE
EVALUATING CLINICAL AND PATIENT-REPORTED OUTCOMES (PROS) FOR PATIENTS WITH DIABETES PARTICIPATING IN A COMPREHENSIVE DISEASE MANAGEMENT PROGRAM
PILOT STUDY OF CLINICIAN ATTITUDES TO PUMP THERAPY
EMPIRIC PSYCHOLOGICAL TYPING OF PATIENTS WITH TYPE 2 DIABETES MELLITUS TREATED ORALLY, AND CORRESPONDING GLYCAEMIC CONTROL/RESULTS FROM THE SETT2D SURVEY
PSYCHOMETRIC EVALUATION OF THE DIABETES SYMPTOM CHECKLIST- REVISED (DSC-R)
EFFECTS OF AN INTENSIFIED THERAPY WITH INSULIN GLARGINEAND INSULINE GLULISINE ON PATIENT REPORTED OUTCOMES IN DIABETES MELLITUS
THE TRANSLATION AND LINGUISTIC VALIDATION OF THE INSULIN TREATMENT SATISFACTION QUESTIONNAIRE (ITSQ) FOR USE IN EASTERN EUROPE
TREATMENT SATISFACTION IS POSITIVELY ASSOCIATED WITH GLYCEMIC CONTROLAND NEGATIVELY ASSOCIATED WITH PATIENT REPORTED EXPERIENCE OF HYPOGLYCEMIC SYMPTOMS AMONG PATIENTS WITH TYPE-2 DIABETES MELLITUS (T2DM) ON ORAL ANTI-HYPERGLYCEMIC AGENTS (OHA) IN EUROPE
BARRIERS TO INSULIN THERAPY QUESTIONNAIRE
COMPARISONS BETWEEN ITEQAND DTSQ IN A SAMPLE OF TYPE 2 DIABETES MELLITUS PATIENTS
THE DIABETES MEDICATION SATISFACTION TOOL (DMSAT)
TIME-AND-MOTION EVALUATION OF DIFFERENT GROWTH HORMONE FORMULATIONS
ASSESSING PATIENTS' RISKS OF BLOOD TRANSFUSIONS
BUDGET IMPACT (BI) OF PARENTERAL IRON TREATMENT OF IRON DEFICIENCY ANAEMIA (IDA) IN SWITZERLAND
CLINICO-ECONOMICAL ANALYSIS OF BORTEZOMIB VS DEXAMETHASONE IN RECURRENT OR TREATMENT-RESISTANT MULTIPLE MYELOMA IN RUSSIA
CLINICO-ECONOMICAL ANALYSIS OF FERRUM LEKVS FENULS IN IRON-DEFICIENT ANEMIA IN ELDERLY PATIENTS
ADVATE IS COST-EFFECTIVE INVESTMENT IN HEMOPHILIA A TREATMENT WHEN PATHOGENS EMERGE—A SCENARIO-BASED ECONOMIC AND POSITIVE INVESTMENT INTERVAL (PII) EVALUATION
COST-EFFECTIVENESS OF INTRAVENOUS IRON VERSUS ORAL IRON IN ANEMIA TREATMENT IN ONCOLOGY, CHRONIC KIDNEY DISEASE AND POST-PARTUM PATIENTS
COST SIMULATION OF NOVOSEVEN VERSUS FEIBAAND ITT-F8 FOR PRIMARY PROPHYLAXIS TREATMENT OF HAEMOPHILIA A/B PATIENTS WITH INHIBITORS
COST-MINIMIZATION ANALYIS OF DARBEPOETIN-α VERSUS EPOETIN-β IN DIALYSED PATIENTS
COST OF ILLNESS OF DIFFUSE LARGE B-CELL LYMPHOMA IN RUSSIA
>COST OF TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES (MDS) IN GERMANY
COST UTILITY OF KNEE SURGERYWITH RECOMBINANT ACTIVATED FACTORVII (RFVIIA) IN HEMOPHILIA PATIENTS WITH INHIBITORS
COST-EFFECTIVENESS OF DASATINIBVS IMATINIB 800 MG/ DAY IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA IN SPAIN
THE EFFECT OF RESTRICTING FERTILITY SERVICES IN GERMANY
PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) CHALLENGE TRANSFUSION RESOURCES NOW AND IN THE FUTURE
POSITIVE INVESTMENT INTERVAL (PII)AND PAYBACK PERIOD (PP) OFFER DIFFERENT INTERPRETATIONS IN HEALTH TECHNOLOGY INVESTMENT DECISIONS
PHM16
RECOMBINANT ACTIVATED FACTORVII (RFVIIA)VS. ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE (APCC) FOR ON-DEMAND TREATMENT OF JOINT BLEEDS IN HEMOPHILIACS WITH INHIBITORS
BEST-WORST CASE SCALING IN DISCRETE CHOICE EXPERIMENTS
USING THE EQ-5DTO MONITOR HEALTH-RELATED QUALITY OF LIFE OVERTIME IN THE CATALAN HEALTH INTERVIEW SURVEY
VALUE OF TRANSFUSION-FREE LIVING IN MDS
UK COMMUNITY DERIVED UTILITIES USING TIME TRADE OFF FOR ORAL VERSUS SUBCUTANEOUS IRON CHELATION THERAPY FORTHETREATMENT OF CHRONIC IRON OVERLOAD
THE EMOTIONAL AND PHYSICAL BURDEN OF INJECTIONS ON PATIENTS UNDERGOING IVF
PATIENTS', PHYSICIANS'AND PHARMACISTS' PREFERENCES TOWARDS COAGULATION FACTOR CONCENTRATES TO TREAT PATIENTS WITH INHIBITORS
PRESCRIBING PATTERNS, PREDICTORS, AND COSTS ASSOCIATED WITH ANTIDEPRESSANT TREATMENTS FOR PERSONS WITH MAJOR DEPRSSIVE DISORDER (MDD) AND COMORBID PAIN
A REVIEW OF PUBLISHED STUDIES ON THE BURDEN OF GENERALIZED ANXIETY DISORDER (GAD) IN GERMANY
EFFECTIVENESS OF OLANZAPINE TREATMENT FOR SCHIZOPHRENIA
EFFICACY OF ANTIPSYCHOTICS IN NEGATIVE SYMPTOMS OF SCHIZOPHRENIA
THE COMPARATIVE EFFICACY OF SECOND-GENERATION ANTIDEPRESSANTS FORTHE ACUTE-PHASE TREATMENT OF MAJOR DEPRESSIVE DISORDER
ATTAINING REMISSION OF DEPRESSIVE SYMPTOMS IN THE PIVOTAL RANDOMISED CLINICAL TRIALS OF DULOXETINE IN MAJOR DEPRESSION. WHICH ARE THE MOST EFFICACIOUS DOSES?
TREATMENT DURATION WITH ORAL AND LONG ACTING INJECTABLE FORMULATIONS OF TYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA
RISPERIDONE LONG-ACTING INJECTION (RLAI) IN THE TREATMENT OF SCHIZOPHRENIA
TREATMENT RETENTION WITH RISPERIDONE LONG ACTING INJECTION (RLAI) IN EUROPEAN PATIENTS WITH SCHIZOPHRENIA
REDUCTION IN SUICIDAL IDEATION, VIOLENT BEHAVIOUR, AND SELF INJURY AFTER TREATMENT WITH RISPERIDONE LONG-ACTING INJECTION (RLAI)
RISPERIDONE LONG-ACTING INJECTION (RLAI) IN THE TREATMENT OF SCHIZOPHRENIA
24-MONTH TREATMENT DISCONTINUATION RATES IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG ACTING INJECTION (RLAI) VERSUS ORAL ANTIPSYCHOTICS
IMPROVEMENTS IN ILLNESS SEVERITY AND FUNCTIONING IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG-ACTING INJECTION (RLAI)
REMISSION IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG-ACTING INJECTION (RLAI)
PREVALENCE OF TREATMENT RESISTANT DEPRESSION IN USUAL CARE IN THE UNITED STATES
ASSOCIATION BETWEEN ATYPICAL ANTIPSYCHOTIC USE AND TREATMENT-EMERGENT DIABETES, HYPERLIPIDEMIA, AND OBESITY
COSTS OF PRESCRIPTION OPIOID ABUSE
PRESCRIBING PATTERN OF CITALOPRAM AND ESCITALOPRAM IN THE CANTON OF GENEVA
COMORBIDITYAND COSTS IN GENERALIZED ANXIETY DISORDERS AND FIBROMYALGIA SYNDROME IN THE PRIMARY CARE SETTING (PCS)
RESOURCE USE AND COSTS ASSOCIATED WITH CHANGES IN ANTIDEPRESSANT TREATMENT IN A MANAGED CARE POPULATION WITH MAJOR DEPRESSIVE DISORDER
THE COST-EFFECTIVENESS OF RISPERIDONE LONG-ACTING INJECTABLE IN SWEDEN
A PHARMACOECONOMIC ANALYSIS OF COMPLIANCE GAINS ON ANTIPSYCHOTIC MEDICATIONS
COST-E FFECTIVENESS OF OLANZAPINE VERSUS GENERIC RISPERIDONE AND OTHER ANTIPSYCHOTICS IN STANDARD ORAL FORMULATIONS IN PATIENTS WITH SCHIZOPHRENIA IN THE US
THE COST EFFECTIVENESS OF PALIPERIDONE EXTENDED-RELEASE OROS IN SWEDEN, FINLAND, DENMARK AND NORWAY
COST EFFETIVENESS OF AMISULPRID IN THE TREATMENT OF SCHIZOPHRENIA
USING THE NET-BENEFIT REGRESSION APPROACH TO COMPARE THE COST-EFFECTIVENESS OF HALOPERIDOL, OLANZAPINE AND RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
COST-EFFECTIVENESS OF DULOXETINE VS.VENLAFAXINE XRAND SSRIS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN PRIMARY AND SECONDARY CARE IN SPAIN
A PHARMACOECONOMIC EVALUATION OF ESCITALOPRAM VS. PAROXETINE IN THE TREATMENT OF GENERALIZED ANXIETY DISORDER IN NORWAY
SWITCHING FROM BRANDED TO GENERIC RISPERIDONE IN PATIENTS WITH SCHIZOPHRENIA
DIRECT COSTS ASSOCIATED WITH MILD COGNITIVE IMPAIRMENT IN PRIMARY CARE
A REVIEW OF PUBLISHED STUDIES ON THE BURDEN OF GENERALIZED ANXIETY DISORDER (GAD) IN THE UNITED KINGDOM (UK)
HEALTH RESOURCES CONSUMPTION AND COST OF MANIC EPISODE IN SPAIN
AN EVALUATION OF HEALTH CARE COSTS WITH A DISEASE MANAGEMENT PROGRAM FOR ADULTS WITH SCHIZOPHRENIA IN A MEDICAID POPULATION USING PROPENSITY SCORE MATCHING
A PHARMACOECONOMIC OUTCOMES ANALYSIS COMPARING RISPERIDONE LONG-ACTING INJECTION AND CONVENTIONAL DEPOT ANTIPSYCHOTICS
SERTINDOLE IN THE TREATMENT OF SCHIZOPHRENIA IN POLAND
A COST-UTILTY ANALYSIS OF ATOMOXETINE AGAINST CURRENT STIMULANT THERAPIES FOR THE TREATMENT OF CHILDREN WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GERMANY
PAIN IN DEPRESSION AND PRODUCTIVITY LOSS—(RESULTS FROM UK SUBSET OF THE EUROPEAN FACTORS INFLUENCING DEPRESSION ENDPOINTS RESEARCH (FINDER) STUDY)
INFLUENCE OF BEHAVIOURAL SYMPTOMS ON RESOURCES USE IN DEMENTIA
ESTIMATION OF THE RESOURCE UTILIZATION AND METABOLIC CONTROL ASSOCIATED WITH DEPRESSIVE SYNDROME IN PATIENTS WITH STROKE
IMPACT OF AN INSPECTOR'S STAMP APPROVAL POLICY INTO THE ATYPICAL ANTIPSYCHOTIC MARKET IN ANDALUSIA (SPAIN)
A MULTI-CENTER STUDY OF ANTIPSYCHOTIC MEDICATION USE, TREATMENT DYNAMICS AND PATIENT SYMPTOMATOLOGY IN SPAIN. RESULTS FROM ANTIPSYCHOSISMONITOR INITIATIVE
THE PREVALENCE OF POTENTIAL DRUG-DRUG INTERACTIONS ASSOCIATED WITH ATYPICAL ANTIPSYCHOTICS WITHIN ONTARIO DRUG BENEFIT CLAIMS
POTENTIAL DRUG-DRUG INTERACTIONS WITH RISPERIDONE AND THE RISK OF DISCONTINUATION
ES2/PMH44
THE IMPACT OF CHANGES IN ANTIDEPRESSANT DRUG TREATMENT IN ELDERLY NURSING HOME (NH) PATIENTS—AREAS OF POTENTIAL CARE DETERIORATION DUE TO FORMULARY POLICIES
THE SENSITIVITYTO CHANGE OF THE HAMILTON (HAMD) AND THE MONTGOMERY-ASBERG (MADRS) SCALES AS OUTCOME MEASURES IN ANTIDEPRESSANT TRIALS
DEVELOPING COST-EFFECTIVE FORMULARIES
IMPACT OF COMORBIDITY ON EQ-5D
SF-36 AND EQ-5D QUALITY OF LIFE INSTRUMENTS IN MAJOR DEPRESSIVE DISORDER PATIENTS
A BELGIAN PILOT PROJECT TESTING THE FEASIBILITY AND ACCEPTABILITY OF SHORT MESSAGE SERVICE (SMS)TEXT MESSAGING TO PATIENTS TREATED WITH QUETIAPINE
ADHERENCE OF ALZHEIMER PATIENTS TO ANTIDEMENTIA DRUGS
USAGE AND PERSISTENCY OF ATYPICAL ANTI-PSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA
ADHERENCE AND SWITCHING WITH ANTIDEPRESSANTS
PRELIMINARY VALIDATION OF THE ENGLISH VERSION OF THE SCHIZOPHRENIA QUALITY OF LIFE (S-QOL) SCALE
DEVELOPMENT AND VALIDATION OF THE SLEEP IMPACT SCALE FOR INSOMNIA
A REVIEW OF INSTRUMENTS USED TO ASSESS THE IMPACT OF ALCOHOLISM ON QUALITY OF LIFE
EFFECTIVENESS OF A PSYCHOSOCIAL INTERVENTION PROGRAM FOR CAREGIVERS OF PATIENTS WITH ALZHEIMER'S DISEASE IN THE PREVENTION OR REDUCTION CAREGIVER BURDEN EDUCA STUDY
IMPROVED SLEEP IMPACT IN GENERALIZED ANXIETY DISORDER WITH ZOLPIDEM TARTRATE EXTENDED-RELEASE
LINGUISTIC VALIDATION OF THE HADS FOR USE IN INTERNATIONAL STUDIES
A PHARMACOECONOMIC COMPARISON OF ESCITALOPRAM AND DULOXETINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN THE UNITED KINGDOM
ACUTE EFFECTS OF SILDENAFIL ON ECHOCARDIOGRAGHIC PARAMETERS IN PATIENTS WITH PRIMARY PULMONARY HYPERTENSION
A COST-MINIMIZATION ANALYSIS COMPARING MOXIFLOXACIN VERSUS LEVOFLOXACIN AND CEFTRIAXONE FOR THE TREATMENT OF PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA
COSTS OF COPD IN SWEDEN ACCORDING TO DISEASE SEVERITY
RELATIONSHIP BETWEEN TIME OF DURATION OF COPD AND FREQUENCY OF DISEASE EXACERBATIONS
REDUCTION IN TOTAL TREATMENT COSTS THROUGH IMPROVED PHARMACEUTICAL TREATMENT OF OBSTRUCTIVE AIRWAY DISEASES
ECONOMIC BURDEN OF DISEASE OF PULMONARY ARTERIAL HYPERTENSION IN GERMANY
ANALYSIS OF THE PREDICTIVE ABILITY OF DIAGNOSTIC COST GROUPS, RXGROUPS, AND PRIOR COST FORTEXAS MEDICAID COPD PATIENTS
S-MEDDIAL PROJECT OF COOPERATION WITH PEDIATRICIANS ON PROVIDING INDIVIDUAL FEEDBACK ON ANTIBIOTICS PRESCRIPTION IN ORDERTO IMPROVE PRESCRIPTION HABITS AND TO RATIONALIZE DRUG SPENDING
ECONOMIC EFFECTS AND SUSTAINABILITY OF A STRUCTURED CARE PROGRAMME FOR COPD PATIENTS
TREATMENT COSTS ASSOCIATED WITH COMMUNITY ACQUIRED PNEUMONIA BY COMMUNITY LEVEL OF ANTIMICROBIAL RESISTANCE
MARKOV MODEL FOR COPD
MAPPING THE EQ-5D FROM THE ST. GEORGE'S RESPIRATORY QUESTIONNAIRE IN A CLINICAL TRIAL OF COPD TREATMENTS—RESULTS FROM THE OPTIMAL TRIAL
CEPOC STUDY
THE IMPACT OF SALMETEROL/FLUTICASONE PROPIONATE COMBINATION ON QUALITY OF LIFE OF ASTHMA AND COPD PATIENTS
EQ-5D UTILITIES ASSOCIATED WITH LEVELS OF COPD SEVERITY
DEVELOPMENT OF PREFERENCE-BASED EQ-5D UTILITY VALUES FORTHE ST GEORGE'S RESPIRATORY QUESTIONNAIRE-CHRONIC OBSTRUCTIVE PULMONARY DISEASE (SGRQ-COPD)
SELECTION OF UTILITY INSTRUMENTS FORASTHMAAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
A PROCESS FOR DEVELOPING A PATIENT-CENTERED CONCEPTUAL FRAMEWORK FOR DYSPNEA AND RELATED FUNCTIONAL LIMITATIONS IN COPD
SEASONAL VARIATION OF TRANSIENT ISCHEMIC ATTACK (TIA) IN HUNGARY
A CRITICAL REVIEW OF PUBLISHED ECONOMIC MODELLING STUDIES IN ISCHAEMIC STROKE
STROKE SURVIVORS' CHANGE IN HEALTH RELATED QUALITY OF LIFE OVERTIME AS MEASURED BYTHE STROKE IMPACT SCALE
EFFECT OF LAUGHTER THERAPY ON STRESS AND HEALTH-RELATED QUALITY OF LIFE IN HEMODIALYSIS PATIENTS
COMPARING THE CLINICAL OUTCOMES FOLLOWING URINARY INCONTINENCE TREATMENT BY DIFFERENT TYPE OF SURGERY
REIMBURSEMENT INCENTIVE FOR PERITONEAL DIALYSIS MAY GENERATE BUDGET SAVINGS FOR ROMANIA
IN THE UNITED KINGDOM, AN INCREASED UTILISATION OF PERITONEAL DIALYSIS THERAPY COULD LEAD TO AN INCREASE IN THE NUMBER OF PATIENTS BEING TREATED FOR RENAL REPLACEMENT THERAPY (RRT)
RETROSPECTIVE PHARMACOECONOMIC STUDY OF THE USE OF CYCLOSPORINE A MICROEMULSION (SANDIMMUN® NEORAL®) IN COMPARISON WITH CYCLOSPORINE A GENERICS FOR IMMUNOSUPPRESSION FOLLOWING KIDNEY TRANSPLANTATION
RETROSPECTIVE PHARMACOECONOMIC STUDY OF THE USE OF CYCLOSPORINE A MICROEMULSION (SANDIMMUN® NEORAL®) IN COMPARISON WITH TACROLIMUS (PROGRAF®) FOR IMMUNOSUPPRESSION FOLLOWING KIDNEY TRANSPLANTATION
A COST-MINIMIZATION ANALYSIS OF OXYBUTYNIN (TRANSDERMAL DELIVERY SYSTEM) COMPARED TO TOLTERODINE (TABLETS) IN THE TREATMENT OF PATIENTS WITH URGE OR MIXED URINARY INCONTINENCE IN SWEDEN
CMA OF MYCOPHENOLAN MOFETIL (MMF; CELLCEPT) OR TACROLIMUS (TAC; PROGRAF) IN KIDNEYTRANSPLANT IMMUNOSUPPRESSIVE THERAPY SCHEMES FROM PUBLIC PAYER'S PERSPECTIVE IN POLAND
HEALTH STATUS AND COSTS OF PATIENTS UNDERGOING HAEMODIALYSISTREATMENT IN HUNGARY
DIRECT COST OF URINARY INCONTINENCE OF ICELANDIC WOMEN, 16 YEARS AND OLDER IN THEYEAR 2004
THE COST OF END STAGE RENAL DISEASE IN GREECE
THE ECONOMIC BURDEN OF HAEMODIALYSIS IN GREECE DURING 2006
COST OF DIALYSIS IN A UK SETTING—A MULTICENTRE MICROCOSTING STUDY
TIME SPENT ON ANAEMIA MANAGEMENT WITH ERYTHROPOIETIN STIMULATING AGENTS (ESA) IN HAEMODIALYSIS CENTRES
AN INTERNATIONAL ECONOMIC EVALUATION OF SEVELAMER HYDROCHLORIDE VERSUS CALCIUM-BASED PHOSPHATE BINDERS IN PATIENTS NEW TO DIALYSIS
GLOBAL ECONOMIC EVALUATIONS OF DIALYSIS TREATMENT MODALITIES
ENDOSCOPIC INJECTION VERSUS ANTIBIOTIC PROPHYLAXIS IN THE REDUCTION OF URINARYTRACT INFECTIONS IN PATIENTS WITH VESICOURETERAL REFLUX
INCREASING MARKET SHARE OF PRIVATE DIALYSIS CENTRES FROM HEALTH INSURANCE EXPENDITURES IN HUNGARY
TREATMENT OUTCOMES AND MEDICAL CARE OF PATIENTS WITH NEUROGENIC DETRUSOR OVERACTIVITY (NDO) RECEIVING BOTULINUM TOXIN A (BOTOX®) THERAPY
A COST EFFECTIVENESS ANALYSIS OF SOLIFENACIN COMPARED WITH EXTENDED-RELEASE TOLTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER
THE IMPACT OF ICODEXTRIN ON QUALITY OF LIFE IN DIABETIC PATIENTS ON PERITONEAL DIALYSIS OVERTIME
AN OBSERVATIONAL STUDY ON THE HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH A NEUROGENIC OVERACTIVE BLADDER TREATED WITH TOLTERODINE ER
ILLNESS REPRESENTATIONS IN RENAL TRANSPLANT RECIPIENTS
UTILIZING AN INTERNET-BASED SYSTEM TO DELIVER A PHARMACY-CENTRIC ALERT AND INTERVENTION IN A MANAGED CARE SETTING
ISSUES WHEN COMPARING COSTS AND EFFECTS OF INHALED ASTHMA AND COPD MEDICATIONS
REVIEWING THE REIMBURSEMENT STATUS OF DRUGS AGAINST ASTHMA, COPD AND COUGHS
DEVELOPMENT AND VALIDATION OF A CAREGIVER GASTROENTERORITIS KNOWLEDGE QUESTIONAIRE
QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS AND TOXICITY (Q-TWIST) OF FOTEMUSTINE COMPARED WITH DACARBAZINE IN PATIENTS WITH DISSEMINATED MALIGNANT MELANOMA
RETROSPECTIVE CHART REVIEW OF THE MANAGEMENT OF HAND-FOOT SYNDROME IN THE TREATMENT OF COLORECTAL CANCER
ECONOMIC IMPACT OF SECOND-AND THIRD-LINE ERLOTINIB TREATMENT OF NON SMALL-CELL LUNG CANCER
COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF USING HEXAMINOLEVULINATE (HEXVIX) CYSTOSCOPY COMPARED TO WHITE LIGHT CYSTOSCOPY IN BLADDER CANCER PATIENTS
THE IMPORTANCE OF A RATIONAL USE OF HIGH COSTING CHEMOTHERAPY AGENTS IN A CHEMOTHERAPY UNIT OF A TERTIARY CANCER HOSPITAL IN BRAZIL
HOSPITALIZATION COSTS FOR TWO METHODS OFTSH STIMULATION DURING THE RADIOIODINE ABLATION IN THYROID CANCER PATIENTS
PRIMARY PROPHYLAXIS AGAINST FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS COST-EFFECTIVE COMPARED WITH FILGRASTIM IN NON-HODGKIN'S LYMPHOMA PATIENTS RECEIVING CHOP-21 IN SPAIN
A COST-CONSEQUENCE ANALYSIS OF DARBEPOETIN ALFA ADMINISTERED EVERY 3 WEEKS (Q3W DA) COMPARED TO WEEKLY EPOETIN ALFA (QW EA) OR EPOETIN BETA (QW EB) IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA (CIA)
COST-EFFECTIVENESS OF SUPERFICIAL BLADDER CANCER SURVEILLANCE IN WHICH CYSTOSCOPY IS PARTLY REPLACED BY MICROSATELLITE ANALYSIS
COST-EFFCTIVENESS ANALYSIS OF ERLOTINIB COMPARED WITH DOCETAXEL AND PEMETREXED FOR SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN TAIWAN
COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS AFTER FIRST-LINE FAILURE OF IMATINIB IN CHRONIC MYELOID LEUKEMIA (CML) IN AUSTRIA
COST-EFFECTIVENESS OF TARGETED ONCOLOGY THERAPIES
ASSESSMENT OF THE COST-EFFECTIVENESS IN AUSTRALIA OF CETUXIMAB IN THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CANCERS OF THE HEAD AND NECK
COST-EFFECTIVENESS OF EXEMESTANE VS. TAMOXIFEN IN POST-MENOPAUSAL WOMEN WITH EARLY BREAST CANCER IN GERMANY
ESTIMATING THE COST EFFECTIVENESS OF PROPHYLACTIC CERVICAL CANCER VACCINATION IN IRELAND USING A MATHEMATICAL MODEL
COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR HER-2 POSITIVE EARLY BREAST CANCER IN TAIWAN
COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB THERAPY IN PATIENTS WITH EARLY HER-2 POSITIVE BREAST CANCER IN BRAZIL
SUNITINIBVS. INTERFERON-ALPHA (IFN-ALPHA) IN FIRST-LINE METASTATIC RENAL CELL CARCINOMA (MRCC)
A COST-CONSEQUENCE ANALYSIS OF DARBEPOETIN ALFA ADMINISTERED EVERY 3 WEEKS (Q3W DA) COMPARED TO WEEKLY EPOETIN ALFA (QW EA) OR EPOETIN BETA (QW EB) IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA (CIA)
COST-EFFECTIVENESS OF CETUXIMAB (ERBITUX®) IN COMBINATION WITH RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN THE TREATMENT OF LOCALLY ADVANCED HEAD AND NECK CANCER IN THE UNITED KINGDOM
A HEALTH ECONOMIC EVALUATION OF HEXVIX AS ADJUNCT TO STANDARD WHITE LIGHT CYSTOSCOPY IN THE MANAGEMENT OF SUPERFICIAL BLADDER CANCER
COST-EFFECTIVENESS OF SUNITINIB AS SECOND LINE TREATMENT IN PATIENTS WITH METASTATIC RENAL CANCER IN BELGIUM
PRIMARY PROPHYLAXIS AGAINST FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS COST-EFFECTIVE COMPARED WITH FILGRASTIM IN NON-HODGKIN'S LYMPHOMA PATIENTS RECEIVING CHOP-21 IN ITALY
COST-EFFECTIVENESS ANALYSIS OF 5HT3 RECEPTOR ANTAGONISTS FOR PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING
PHARMACOECONOMIC EVALUATION OF CAPECITABINE (XELODA) FOR GASTRIC CANCER IN THE UNITED KINGDOM
INNOVATION OVER THE PRODUCT LIFE CYCLE
COST-EFFECTIVENESS OF HUMAN INTERFERON-ALPHAAS ADJUVANT TREATMENT FOR PATIENTS WITH RESECTED CUTANEOUS MALIGNANT MELANOMA IN STAGE IIB & III
ECONOMIC EVALUATION OF SWITCHING TO EXEMESTANE AT 2–3 YEARS VERSUS CONTINUING TAMOXIFEN AS ADJUVANT THERAPY IN EARLY BREAST CANCER
COST-EFFECTIVENESS OF MAINTENANCE RITUXIMAB TREATMENT AFTER SECOND LINE THERAPY IN PATIENTS WITH FOLLICULAR NON-HODGKIN'S LYMPHOMA IN SWEDEN
THE ECONOMIC BENEFITS OF TEGAFUR WITH URACIL (UFTORAL) IN FIRST- LINE METASTATIC COLORECTAL CANCER
COST MINIMIZATION ANALYSIS OF CAPECITABINE+CISPLATIN IV VS 5-FLUORURACIL IV+CISPLATIN IV AS FIRST LINE THERAPY FOR ADVANCED GASTRIC CANCER FROM THE BRAZILIAN SOCIETAL PERSPECTIVE
COST-MINIMISATION ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL OR PEMETREXED AS SECOND-LINE THERAPY FOR NON-SMALL-CELL LUNG CANCER (NSCLC) FROM THE PERSPECTIVE OF A PRIVATE PAYER IN BRAZIL
COST-MINIMIZATION ANALYSIS OF ONCE-PER-CYCLE FIXED-DOSE ADMINISTRATION OF PEGFILGRASTIM VERSUS DAILY FILGRASTIM FOR THE PROPHYLAXIS OF CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA IN BRAZIL
COST MINIMIZATION ANALYSIS OF INTRA-VENOUS BIPHOSPHONATES THERAPIES AVAILABLE IN BRAZIL FOR THE PROPHYLAXIS OF SKELETAL EVENTS (SE) IN BREAST CANCER PATIENTS WITH BONE METASTASIS
ASSESSING THE IMPACT ON STAFF RESOURCES AND PATIENT WAITING TIME OF A SWITCH FROM IV TO ORAL CHEMOTHERAPY WITH VINORELBINE
ECONOMIC EVALUATION OF ERLOTINIB, DOCETAXEL AND PEMETREXED AS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC). A COST-MINIMIZATION IN ITALIAN HOSPITALS
RESOURCE USE AND TIME SAVINGS IN SPAIN LINKED WITH NEW CHEMOTHERAPY PRESENTATIONS
COST-ANALYSIS OF XELOXVS. FOLFOX-4 ± BEVACIZUMAB (BEV) IN METASTATIC COLORECTAL CANCER (MCRC) IN AN ITALIAN HOSPITAL SETTING
THE COST OF TREATING AND MANAGING ABNORMAL CERVICAL CONDITIONS IN IRELAND
HEXVIX FLUORESCENCE CYSTOSCOPY FOR NON-INVASIVE BLADDER CANCER MANAGEMENT
HEXVIX FLUORESCENCE CYSTOSCOPY FOR NON-INVASIVE BLADDER CANCER MANAGEMENT
COST ANALYSIS OF SEPSIS MANAGEMENT AFTER MYELOSUPPRESSIV CHEMOTHERAPY IN NSCLC AND LYMPHPOMA PATIENTS
COST OF INTRAVENOUS ADMINISTRATION OF BISPHOSPHONATES IN PATIENTS WITH METASTATIC BREAST CANCER
ADJUVANT TRASTUZUMAB TREATMENT IN EARLY STAGE BREAST CANCER
UK COST-EFFECTIVENESS ANALYSES OF DOCETAXEL VERSUS GENERIC PACLITAXEL ONCE WEEKLY AND NAB-PACLITAXEL IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER (MBC) PROGRESSED AFTER ANTHRACYCLINE CHEMOTHERAPY
A COST UTILITY ANALYSIS OF MAINTENANCE RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR NON HODGKINS LYMPHOMA (NHL) IN THE UNITED KINGDOM
COST-UTILITY ANALYSIS OF OXALIPLATIN IN THE ADJUVANT TREATMENT OF COLON CANCER IN HUNGARY
SUNITINIB MALATE PROVIDES ADDITIONAL SURVIVAL AND VALUE FOR MONEY AS A SECOND LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC)—AN ECONOMIC EVALUATION USING BAYESIAN APPROACH
COST-UTILITY ANALYSIS OF MAINTENANCE THERAPY WITH RITUXIMAB FOR FOLLICULAR LYMPHOMA IN BRAZIL
COST SHIFTING EFFECT IN DRG BASED ANTI-CANCER THERAPIES IN HUNGARY
COMPARING THE BURDEN OF CANCER AND OTHER DISEASES WITH THE ECONOMIC RESOURCES ALLOCATED TO THOSE DISEASES
GAP BETWEEN TREATMENT COST OF AND MORTALITY DUE TO CERVICAL CANCER IN HUNGARY
EFFECT OF THE HUNGARIAN ORGANIZED NATIONWIDE CERVICAL CANCER SCREENING PROGRAMME ON THE COVERAGE OF WOMEN OVER 64 YEARS
INCREASING EXPENDITURES FOR ONCOLOGY MEDICATIONS
THE IMPACT OF 21-GENE RT-PCR ASSAY ON REAL LIFE TREATMENT DECISIONS IN N-, ER+ EARLY-STAGE BREAST CANCER PATIENTS
INTERNATIONAL INCIDENCE OF MEN WITH UNCERTAIN INDICATION FOR RADICAL PROSTATECTOMY
BASIC ATTITUDE TO USE OF GENERIC ANTI-CANCER DRUGS FOR BREAST CANCER TREATMENT IN JAPAN
BREAST CANCER SCREENING PROGRAMS
TREATMENT PATTERNS FOR PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM) IN GERMANY
IMPLEMENTATION AND EVALUATION OF CLINICAL PATHWAYS IN AN ONCOLOGY ELECTRONIC MEDICAL RECORD
MULTI-STATE SURVIVAL ANALYSIS IN COST-EFFECTIVENESS STUDIES
USE OF A 5-LEVEL EQ-5D IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA
META-ANALYTIC, TRIAL-LEVEL APPROACH TO VALIDATION OF PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT IN ADVANCED BREAST CANCER
CLINICALLY IMPORTANT DIFFERENCE IN QUALITY-ADJUSTED SURVIVAL IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE TREATMENT WITH TEMSIROLIMUS (TEMSR) OR INTERFERON-A (IFN)
RESULTS FROM MABEL
DEFINING HEALTH STATE UTILITIES FOR HAND-FOOT-SYNDROME
ESTIMATION OF IMPORTANT DIFFERENCES IN EQ-5DVAS SCORES IN CANCER
SENSITIVITY TO CHANGE OF THE PERFORM QUESTIONNAIRE (PQ) IN CANCER PATIENTS REPORTING IMPROVEMENT OR DETERIORATION OF THEIR CANCER-RELATED FATIGUE
PATIENT-REPORTED IMPAIRMENT OF EUROQOL HEALTH STATES AND PREFERENCE-WEIGHTED UTILITY IN ADVANCED RENAL CELL CARCINOMA IN A RECENT CLINICAL TRIAL
UTILITYVALUES FOR HEALTH STATES FOR CHRONIC MYELOGENOUS LEUKAEMIA (CML)
CONJOINT ANALYSIS ATECHNIQUE TO DEVELOP A QUESTIONNAIRE OF TREATMENT PREFERENCES IN PATIENTS WITH LUNG CANCER
HEALTH-RELATED QUALITY OF LIFE (HRQOL)AND KIDNEY CANCER-RELATED SYMPTOMS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)TREATED WITH SUNITINIB VERSUS INTERFERON (IFN)-ALFA IN A RANDOMISED, MULTINATIONAL PHASE III TRIAL
LINGUISTIC VALIDATION OF THE HOT FLASH DIARY FOR PROSTATE CANCER PATIENTS IN EIGHT LANGUAGES FOR NINE COUNTRIES
PSYCHOSOCIAL CONSEQUENCES OF ABNORMAL AND FALSE-POSITIVE RESULTS IN LUNG CANCER SCREENING
WHAT CHOICES DO MEN FEEL THEY HAVE IN SELECTION OF PROSTATE CANCER TREATMENT?
COMPARISON OF PHYSICIAN AND PATIENT PREFERENCES FOR COLORECTAL CANCER SCREENING USING A DISCRETE CHOICE EXPERIMENT
USE OF BAYESIAN NETWORKS TO SPECIFY NOCTURNAL IOP CONTROL BY PROSTAGLANDIN ANALOGUES ACCORDING TO SEVERAL THRESHOLDS FROM DAY-TIME MEASUREMENTS IN GLAUCOMA PATIENTS
INTRA-OCULAR PRESSURE CONTROL OF XALACOM ® (FIXED LATANOPROSTANDTIMOLOL COMBINATION) AND DUOTRAV ® (FIXED TRAVOPROST AND TIMOLOL COMBINATION) IN DAILY PRACTICE
RANIBIZUMAB (LUCENTIS®) IS A COST-EFFECTIVE TREATMENT OF AGE-RELATED MACULA DEGENERATION (AMD) IN THE GERMAN HEALTH CARE SYSTEM
COST-EFFECTIVENESS ANALYSIS OF FIXED COMBINATION THERAPIES GANFORT, DUOTRAV AND XALACOM IN EUROPEAN COUNTRIES
COST-EFFECTIVENESS MODELING OF LUCENTIS VERSUS USUAL CARE IN AGE RELATED MACULAR DEGENERESCENCE
COST OF CATARACT SURGERY AFTER IMPLANTATION OF THREE INTRAOCULAR LENSES WITH SQUARE EDGES
COST-EFFECTIVENESS OF FIRST EYE CATARACT SURGERY IN ELDERLY WOMEN
A EUROPEAN SURVEY OF PATIENT SATISFACTION WITH SPECTACLES AND THE ASSOCIATED COSTS IN FIVE EUROPEAN COUNTRIES
COST OF STANDARD CARE TREATMENT IN THE UNITED KINGDOM AMONG PATIENTS WITH PROGRESSION OF PRIMARY OPEN ANGLE GLAUCOMA
OXIDATIVE STRESS IN ADVANCED PRIMARY OPEN-ANGLE GLAUCOMA
ESTIMATING NET HEALTH BENEFITS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NV-AMD)
METHODOLOGICAL ISSUES ARISING FROM THREE STUDIES WHICH INCLUDED CONJOINT ANALYSIS IN VISUALLY IMPAIRED PEOPLE
TIME TO DISCONTINUATION OF GLAUCOMA MEDICINES PRESCRIBED SUBSEQUENT TO INITIAL THERAPY
ASSESSMENT OF THE PERSISTENCE DEGREE IN PATIENTS WITH ANTIGLAUCOMA AGENTS AS FIRST LINE MONOTHERAPIES IN SPAIN
HUMANISTIC BURDEN AND HEALTH RESOURCE UTILIZATION AMONG NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD) PATIENTS IN FRANCE
CULTURAL ADAPTATION AND PARTIAL VALIDATION OF THE GLAUCOMA SYMPTOM SCALE (GSS) TO SPANISH
DETERMINATION OF MINIMAL IMPORTANT DIFFERENCES (MIDS) AND INTERPRETATION OF SF-36 SCORES IN PATIENTS SUFFERING FROM MODERATE-TO-SEVERE CROHN'S DISEASE
PROTON PUMP INHIBITORS FOR THE INITIAL TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GORD) SYMPTOMS IN PATIENTS WITH REFLUX OESOPHAGITIS
BUDGET IMPACT OF A UNIVERSAL ROTAVIRUS VACCINATION PROGRAMME WITH ROTATEQ® IN FRANCE
ECONOMIC EVALUATION COMPARING LANSOPRAZOLE AND ESOMEPRAZOLE IN THE ACUTE MANAGEMENT OF UNINVESTIGATED DYSPEPSIA
EVALUATION OF THE COST-EFFECTIVENESS OF CONCOMITANT ORAL AND TOPICAL MESALAZINE TREATMENT VERSUS ORAL TREATMENT ALONE IN MILD-TO-MODERATE ACTIVE ULCERATIVE COLITIS
PHARMACOECONOMIC ANALYSIS OF PROTON PUMP INHIBITORS ON C & D ESOPHAGITISTREATMENT IN SPAIN
COST-EFFECTIVENESS ANALYSIS OF TREATING CHORNIC HEPATITITIS C (CHC) PATIENTS WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN EARLY BEFORE DISEASE PROGRESSES TO MORE ADVANCED STAGE
COST-EFFECTIVENESS OF ESOMEPRAZOLE IN THE TREATMENT OF ADOLESCENT PATIENTS WITH REFLUX OESOPHAGITIS
PHARMACOECONOMIC ANALYSIS OF GERD TREATMENT AFTER OMEPRAZOLE FAILURE IN SPAIN
PGI10
IMPACT OF CONSTIPATION ON HEALTH CARE UTILIZATION AND COSTS IN PATIENTS ON OPIOID THERAPY
THE DUEC (DIGITAL ULCERS ECONOMIC COST) STUDY
THE EPIDEMIOLOGY AND HEALTH CARE RESOURCE USE IN PATIENTS WITH CROHN'S DISEASE
THE EPIDEMIOLOGY AND HEALTHMCARE RESOURCE USE IN PATIENTS WITH ULCERATIVE COLITIS
PERSISTENCE WITH INFLIXIMAB THERAPY REDUCES CROHN'S DISEASE RELATED MEDICAL COSTS
AN EXPLORATORY ANALYSIS OF HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH PEDIATRIC CROHN'S DISEASE
INCREASED INPATIENT UTILIZATION FOLLOWING COLECTOMY IN ULCERATIVE COLITIS IN THE MEDICARE POPULATION
THE QUALITY INDICATORS OF NURSING CARE AMONG PATIENTS WITH ACUTE PANCREATITIS IN HUNGARY
INVESTIGATION OF OTC NSNSAID RATIONAL USE AND GASTROINTESTINAL DISEASES
MAINTENANCE THERAPY WITH INFLIXIMAB REDUCES HOSPITALIZATION AND SURGERY IN CROHN'S DISEASE
THE VALUE OF INFORMATION OF SCREENING FOR HEREDITARY HEMOCHROMATOSIS
ASSOCIATION BETWEEN HEALTH-RELATED QUALITY OF LIFE AND UTILITY SCORES FROM EQ-5D OR SF-6D IN CROHN'S DISEASE
USING DISCRETE CHOICE EXPERIMENTS (DCE)TO MEASURE PREFERENCES FOR TREATMENT OPTIONS
SPANISH CULTURAL ADAPTATION AND VALIDATION OF THE GASTROINTESTINAL SHORT FORM QUESTIONNAIRE (GSFQ)
DEVELOPMENT AND VALIDATION OF PATIENT REPORTED OUTCOMES MEASUREMENT SCALES FOR CROHN'S DISEASE
VALIDATED MEASURES OF HEALTH RELATED QUALITY OF LIFE AND PRODUCTIVITY IN A POPULATION OF PATIENTS REPORTING CHRONIC CONSTIPATION
ESTIMATION OF WEIGHTS FOR THE SPANISH VERSION OF SF-6DTO DERIVE SOCIETAL HEALTH STATE VALUES USING THE SPANISH VERSION OF SF-36V1
IMPACT OF CERTOLIZUMAB PEGOL ON QUALITY-ADJUSTED LIFE-YEARS IN TWO INDUCTION AND MAINTENANCE TRIALS IN PATIENTS WITH ACTIVE CROHN'S DISEASE
UPPER GI SYMPTOMS IN GREEK PATIENTS RECEIVING ASPIRIN/NSAIDS
ECONOMIC ANALYSIS OF THE BAVARIAN BLOOD AND PLASMA MARKET
A DETERMINATION OF TOPICS FOR HEALTH TECHNOLOGY ASSESSMENT IN THAILAND
BUDGET SILO MENTALITY BEHIND THE FORMER IRON CURTAIN
CANADIAN COMPETION DURING A U.S. GENERIC DRUG'S 180-DAY EXCLUSIVITY PERIOD
DOES ENTRY OF GENERIC DRUGS ALWAYS RESULT IN COST-CONTAINMENT? THE HUNGARIAN EVIDENCE
NETWORKING TOWARDS FUNCTIONAL POLICY-TOOLS
INTERNATIONAL COMPARISON OF GENERIC MEDICINE PRICES
THE CHALLENGE OF A LEGITIMATE BUDGET IMPACT RATIONING CRITERION IN DRUG REIMBURSEMENT DECISIONS
INFLUENCE OF POLYPHARMACY BY APPLYING THE ADJUSTED CLINICAL GROUPS CLASSIFICATION IN A SPANISH POPULATION SETTING
COMPLEMENT OR SUBSTITUTE? COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) USE AND PRESCRIPTION DRUG USE AMONG AFRICAN AMERICANS
EFFICIENCY IN DRUG PRESCRIPTION MEASURED BYTHE APPLICATION OF ADJUSTED CLINICAL GROUPS IN FIVE SPANISH PRIMARY CARE CENTRES
RETROSPECTIVE DRUG UTILIZATION REVIEW
THE COST OF WASTED MEDICINES IN PORTUGAL
GENERIC PRESCRIPTION MEDICINES PRICEVARIATION AMONG COMMUNITY PHARMACIES, PUBLIC HOSPITAL PHARMACIES AND DISPENSING DOCTORS IN ZIMBABWE
PREFERENCES FOR DRUG REIMBURSEMENT CRITERIA IN SOUTH KOREA USING DISCRETE CHOICE EXPERIMENTS
ASSESSMENT OF DECISION MAKER NEEDS RELATED TO HEALTH ECONOMIC MODELS AND DATA ANALYSIS TOOLS
RECOMMENDATIONS FROM REIMBURSEMENT AGENCIES FOR ADDITIONAL POST-LAUNCH RESEARCH.THE NEXT HURDLE
HEALTH CARE DECISION-MAKERS'ATTITUDE ON HEALTH ECONOMICS RESEARCH
IMMUNIZATION PROGRAM IN PARAGUAY
THE GENERIC COST-EFFECTIVENESS OF HEALTH CARE
IMPACT OF DISCONTINUITY IN HEALTH INSURANCE ON RESOURCE UTILIZATION
THE GREEK PHARMACEUTICAL EXPENDITURE DATA
RELATIONSHIP BETWEEN RISKS FOR LIFESTYLE-RELATED DISEASES AND MEDICAL EXPENSES AFTER 10 YEARS OF METABOLIC SYNDROME
TRENDS OF PATIENT COSTS PER CASE IN ALBERTA, CANADA
MEDICATION ADHERENCE IN POST-TRANSPLANT IMMUNOSUPPRESSION
THE EFFECT OF INJURY SEVERITYANDTRAUMA CENTER DESIGNATION ON INPATIENT COSTS AND OUTCOMES IN HOSPITAL ADMISSIONS FORTRAUMATIC INJURY INTHE UNITED STATES
A NEW REGRESSION MODEL AND QUALITY PERFORMANCE ADJUSTMENT IN PHYSICIAN ECONOMIC PROFILING
DEVELOPMENT OF THE CAT-HEALTH SYSTEM
THE RELATIONSHIP BETWEEN PHYSICIAN EMPATHY AND SATISFACTION WITH PRIMARY CARE PHYSICIANS
HEALTH OUTCOMES AMONG INDIVIDUALS WITH AND WITHOUT HEALTH INSURANCE IN THE UNITED KINGDOM
EUROPEAN PRICING AND REIMBURSEMENT UPDATE
OBTAINING VALUE FOR MONEY FROM PHARMACEUTICALS
RESULTS AND OUTCOMES OF NICE SINGLE TECHNOLOGY APPRAISALS
EXAMINING INCENTIVES FOR SUBGROUPING IN NICE SUBMISSIONS
PROFILE OF PHYSICIANS' PRESCRIPTION IN GREECE
PATIENT TRANSFER DECREASE AND HEALTH INSURANCE COSTS SAVINGS ASSOCIATED WITH TELEMEDICINE CONSULTATION. EXAMPLE OF THE TELEMEDICINE NETWORK OF “MIDI-PYRéNéES” (RTR)
PHARMACOECONOMIC EDUCATION IN COLLEGES OF PHARMACY—2007
PREVALENCE OF PALLIATIVE CARE NEEDS IN A COMMUNITY-BASED PUBLIC HOSPITAL
PROVISION OF ESSENTIAL MEDICINES AND PHYSICIANS QUALITY PERCEPTION OF ARGENTINA HEALTH CARE SERVICES
ASSOCIATION BETWEEN CENTRAL PRECOCIOUS PUBERTY AND COMORBID MEDICAL ILLNESS
RISK-ADJUSTED MALNUTRITION STATUS AS PREDICTOR FOR CLINICAL OUTCOMES IN HOSPITALIZED PATIENTS (RAMP)
COST ESTIMATES AND METHODOLOGICAL PERSPECTIVE
DRUG COSTS AT THE END OF LIFE
COSTS AND OUTCOMES ASSOCIATED WITH USE OF RECOMBINANT FOLLICLE STIMULATING HORMONE (RFSH) DURING IN VITRO FERTILISATION (IVF) TREATMENT IN A UNITED KINGDOM CENTRE
INPATIENT COSTS AND OUTCOMES ASSOCIATED WITH TRAUMATIC INJURY AMONG PEDIATRICS IN THE UNITED STATES
COST-EFFECTIVENESS OF MAGNETIC RESONANCE IMAGE-GUIDED FOCUSED ULTRASOUND (MRGFUS) FOR THE TREATMENT OF UTERINE FIBROIDS
COST EFFECTIVENESS MODELLING OF ENZYME REPLACEMENT THERAPY FOR MUCOPOLYSACCHARIDOSIS II, AN ULTRA-ORPHAN DISEASE
ESTIMATION OF HEALTH CARE PROFESSIONALS'TIME INPUT USING MULTI-DIMENSIONAL WORK SAMPLING (MDWS)
AN ECONOMIC ASSESSMENT OF THE CONTENT OF HOME PHARMACIES AND SELF MEDICATION PRACTICE AMONG FAMILIES IN SLOVAK REPUBLIC AND SERBIA CITIES
ROLE OF BLACK BOX WARNINGS AND FORMULARY MANAGEMENT
HORMONE REPLACEMENT THERAPY OF MENOPAUSAL WOMEN—ANALYSIS OF PRESCRIPTION PATTERN CHANGES BEFORE AND AFTER THE WHI STUDY USING CLAIMS DATA OF A GERMAN SICKNESS FUND
FRAMEWORK FOR THE COST-EFFECTIVENESS ANALYSIS OF MAMMOGRAPHY SCREENING FOR BREAST CANCER
DESCRIBING YOUR HEALTH TODAY
ADJUSTING FORTRIAL QUALITY IN A META-ANALYSIS
PIH16
PIH17
VALIDITY OF A CHILD-FRIENDLY EQ-5D AS A GENERIC HEALTH OUTCOME INSTRUMENT IN CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS IN GERMANY
TEMPORAL PATTERNS IN HEALTH RELATED QUALITY OF LIFE IN HOSPITALIZED PATIENTS IN THE UNITED KINGDOM
ASSOCIATION BETWEEN METABOLIC SYNDROME AND QUALITY OF LIFE IN MALE STAINLESS STEEL WORKERS
CORRELATES OF PATIENT SATISFACTION WITH PHYSICIAN VISIT
WILLINGNESS TO PAY OF YOUNG GREEK WOMEN FORTHE NEW ANTI-HUMAN PAPILOMA VIRUS VACCINE
BUDGETARY ANALYSIS OF AMBULATORY CARE STRATEGY FOR PATIENTS WITH TRANSIENT ISCHEMIC ACCIDENT (TIA)
BUDGET IMPACT ANALYSIS OF LEVETIRACETAM ADJUNCTIVE THERAPY IN PATIENTS WITH JUVENILE MYOCLONIC EPILEPSY IN SCOTLAND
BUDGET IMPACT OF DOPAMINE AGONISTS IN POLAND
DRUG UTILISATION AND EXPENDITURE ASSOCIATED WITH TREATMENTS OF NEUROLOGICAL DISORDERS
USE OF HEALTH CARE RESOURCES AND CORRESPONDING COSTS IN NEUROLOGICAL DISORDERS IN THE PRIMARY CARE SETTING
COST-EFFECTIVENESS OF GLATIRAMER ACETATE AND NATALIZUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE PRESENCE OF LONG-TERM CLINICAL EVIDENCE
PND7
COST-EFFECTIVENESS ANALYSIS OF AMBULATORY CARE STRATEGY FOR PATIENTS WITH TRANSIENT ISCHEMIC ACCIDENT (TIA) VERSUS THE STANDARD PROTOCOL BASED ON HOSPITALISATION
LEVETIRACETAM ADJUNCTIVE THERAPY FORTHE TREATMENT OF REFRACTORY PRIMARY GENERALISED TONIC-CLONIC SEIZURES
COST EFFECTIVENESS ANALYSES OF RUFINAMIDEVS TOPIRAMATE AND LAMOTRIGINE AS ADJUNCTIVE THERAPIES IN THE TREATMENT OF LENNOX-GASTAUT SYNDROME (LGS) IN THE UNITED KINGDOM
COMPARATIVE ANALYSIS OF MULTIPLE SCLEROSIS COST-EFFECTIVENESS MODELS
MODELING THE CLINICAL AND ECONOMIC CONSEQUENCES OF TREATING RELAPSING FORM OF MULTIPLE SCLEROSIS WITH SUBCUTANEOUS VERSUS INTRAMUSCULAR INTERFERON-BETA-1A
COST-EFFECTIVENESS ANALYSIS OF THE LIDOCAINE 5% MEDICATED PLASTER RELATIVE TO GABAPENTIN AND PREGABALIN FOR POST-HERPETIC NEURALGIA IN GERMANY
COST-EFFECTIVENESS OF PREGABALIN ADD-ON MEDICATION IN PATIENTS WITH REFRACTORY PARTIAL EPILEPSY IN FINLAND
THE COST-UTILITY OF EXELON PATCH IN THE MANAGEMENT OF PATIENTS WITH MODERATE ALZHEIMER'S DISEASE IN THE UNITED KINGDOM
OBJECTIVE COSTS AND PREVALENCE OF COMORBIDITIES DURING THE YEAR FOLLOWING DIAGNOSIS FOR PERSONS WITH AND WITHOUT INSOMNIA
TREATMENT COSTS ASSOCIATED WITH RESTLESS LEGS SYNDROME IN ITALY
HEALTH AND NON-HEALTH RESOURCES UTILIZATION AND DERIVED COSTS OF TREATING UNDER ROUTINE MEDICAL PRACTICE REFRACTORY PAIN ASSOCIATED TO TRIGEMINAL NEURALGIA IN PRIMARY CARE SETTING (PCS)
ECONOMIC EVALUATION OF INTERFERON-Â-1B IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME (CIS)
COST-UTILITY ANALYSIS EVALUATING THE LIDOCAINE 5% MEDICATED PLASTER RELATIVE TO GABAPENTIN AND PREGABALIN FOR POST-HERPETIC NEURALGIA IN GERMANY
INSOMNIA AND SLEEP LOSS
MILD TO MODERATE ALZHEIMER'S DISEASE ASSOCIATED WITH SIGNIFICANT TIME BURDEN TO CAREGIVERS
A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS TREATED WITH GLATIRAMER ACETATE INJECTION OR HIGH-DOSE INTERFERON BETA-1A
TRENDS IN ANTI-ALZHEIMER'S MEDICATION UTILIZATION AND ASSOCIATED PATIENT CHARACTERISTICS IN SPAIN
TREATMENT PATTERNS AND PATIENT CHARACTERISTICS IN PARKINSON'S DISEASE (PD)
USE OF A COUNSELLING GUIDELINE FOR THE DETECTION OF DRUG RELATED PROBLEMS IN PARKINSON'S DISEASE
ESTIMATING MARGINAL COST-EFFECTIVENESS USING A PERSON-LEVEL NET BENEFITS APPROACH WITH AN APPLICATION TO DISEASE-MODIFYING DRUGS IN MULTIPLE SCLEROSIS
COMPARISON OF FOUR PREFERENCE-BASED SF-36/SF-12 ALGORITHMS TO EVALUATE THE COST-EFFECTIVENESS OF TREATMENT FOR PRIMARY INSOMNIA WITH ESZOPICLONE
RETROSPECTIVE MEASUREMENT OF UNCODED DISEASE OUTCOMES IN A CLAIMS DATABASE
ANALYSIS OFTRIPTAN REFILLING BEHAVIOR AMONG FEMALE MIGRAINEURS
DEVELOPMENT OF THE ALZHEIMER'S DISEASE CAREGIVER PREFERENCE QUESTIONNAIRE
ALZHEIMER'S DISEASE PROGRESSION HEALTHY-YEAR EQUIVALENTS
THE RELATIONSHIP BETWEEN THE MEDICATION POSSESSION RATIO AND PATIENT OUTCOMES
A QUALITATIVE STUDY OF THE INDIVIDUALISED IMPACT OF RESTLESS LEGS SYNDROME (RLS) ON QUALITY OF LIFE
MEASURING THE IMPACT OF RESTLESS LEGS SYNDROME (RLS) ON QUALITY OF LIFE
FIT OF THE MIGRAINE PREVENTION ASSESSMENT CLINICAL TOOL (M-PACT) WITH QUALITATIVE DEVELOPMENT GUIDELINES FOR PATIENT REPORTED OUTCOMES
A REVIEW OF PATIENT-REPORTED OUTCOMES THAT COMPLEMENT ASSESSMENTS OF SEIZURE REDUCTION IN ADULT EPILEPSY DRUG TRIALS
LONGITUDINAL PATIENT-REPORTED OUTCOMES (PRO) IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO TRIGEMINAL NEURALGIA
PATIENT-REPORTED OUTCOME (PRO) LABELING CLAIMS IN PARKINSON'S DISEASE
PND40
EFFECTIVENESS OF PRAMIPEXOLE IN THE TREATMENT OF RLS AND THE EFFECT ON WORK PRODUCTIVITY
EFFICACY OF ZOLEDRONIC ACID RELATIVE TO OTHER TREATMENTS FOR VERTEBRAL FRACTURES IN OSTEOPOROSIS
CORRELATION BETWEEN PREDICTORS AND SUBSEQUENT SURGICAL MANAGEMENT FOLLOWING INTERNAL FIXATION OF FEMORAL NECK FRACTURES
THE ROLE OF SURGICAL DELAY ON EARLY MORTALITY IN PATIENTS WITH FEMORAL NECK FRACTURE
ECONOMIC IMPACT OF FRENCH NEW GUIDELINES ON POST-MENOPAUSAL OSTEOPOROSIS DIAGNOSIS
LITERATURE REVIEW ON THE COSTS OF NON-COMPLIANCE IN OSTEOPOROSIS
COST-EFFECTIVENESS OF OSTEOPOROSIS SCREENING CAMPAIGN FOR BELGIAN WOMEN
COST-EFFECTIVENESS SIMULATION MODELING OF THE COMPLIANCE OF 5 MG ZOLEDRONIC ACID ONCE A YEAR VERSUS CURRENT TREATMENTS IN POST-MENOPAUSAL OSTEOPOROSIS
COMPARISON OF THE COST-EFFECTIVENESS OF ZOLEDRONIC ACID 5 MG FORTHE MANAGEMENT OF POST-MENOPAUSAL OSTEOPOROSIS IN THE UK SETTING
COMPARATIVE ANALYSIS OF THE COST-EFFECTIVENESS OF TERIPARATIDE [RHPTH(1–34)] VERSUS RHPTH(1–84)
COST-OF-ILLNESS STUDY OF HIP FRACTURE AMONG KOREAN ELDERLY WOMEN
FALL-RELATED HOSPITALIZATION AND FACILITY COSTS AMONG RESIDENTS RECEIVING LONG-TERM CARE
USE OF OSTEOPOROSIS MEDICATIONS FOLLOWING A FRACTURE
IMPACT OF THE ALLOWABLE GAP ON PERSISTENCE IN THE BISPHOSPHONATE MARKET
COMPARISON OF SF-6DAND EQ-5D UTILITIES IN OSTEOPOROTIC HIP FRACTURE PATIENTS
SUB-ACUTE LACK OF ASTHMA CONTROL AND SUBSEQUENT ACUTE ASTHMA EXACERBATIONS
PREVALENCE OF UNCONTROLLED SEVERE PERSISTENT ASTHMA PATIENTS IN PNEUMOLOGY AND ALLERGY HOSPITAL UNITS IN SPAIN
A BUDGET IMPACT MODEL FOR DETERMINING THE COSTS OF INTRODUCING A NEW EXTRAFINE COMBINATION (BECLOMETHASONE/FORMOTEROL) FORTHETREATMENT OF MODERATE TO SEVERE PERSISTENT ASTHMA IN SPAIN
COST-EFFECTIVENESS ANALYSIS OF OMALIZUMABVS STANDARD THERAPY (ST), IN THE MANAGEMENT OF SEVERE ASHTMA
CLINICO-ECONOMICAL ANALYSIS OF USING BUDESONID/FORMOTEROL INHALER FORTREATMENT OF BRONCHIAL ASTHMA
COST EFFECTIVENESS OF BREATH-OPERATED INHALERS IN UNITED KINGDOM PRIMARY CARE
A PHARMACOECONOMIC EVALUATION OF SUBLINGUAL IMMUNOTHERAPY COMPARED TO SUBCUTANEOUS IMMUNOTHERAPY IN THE TREATMENT OF GRASS POLLEN INDUCED RHINOCONJUNCTIVITIS
COST OF REFRACTORY SEVERE PERSISTENT ASTHMA IN CZECH REPUBLIC—COST OF ILLNESS STUDY
RISK-ADJUSTED COSTS AND OUTCOMES FOR MILD PERSISTENT ASTHMA PATIENTS ON ALTERNATIVE CONTROLLER THERAPIES
ADULT ASTHMA
ECONOMIC EVALUATION OF SECOND-LINE THERAPIES IN ADULT PATIENTS WITH ASTHMA WHEN CONSIDERING COMPLIANCE—AN ANALYSIS FROM A SWEDISH HEALTH CARE PERSPECTIVE
EXTENT OF UNCONTROLLED DISEASE AND ASSOCIATED MEDICAL COSTS IN SEVERE ASTHMA IN THE NETHERLANDS
THE MONTREAL PROTOCOL
PHYSICIANS EDUCATIONAL EFFORTS
EFFECT OF IMMUNOTHERAPY ON DRUG USE AND COST IN RAGWEED POLLEN ALLERGIC DISEASE IN LOMBARDIA
PAA16
PHYSICIAN ADHERENCE TO NATIONAL ASTHMA PRESCRIBING GUIDELINES
USING CLAIMS DATA TO MODELTHE BUDGETARY IMPACT OF A NEW TREATMENT FOR RHINITIS
BI-MODALITY IN DISTRIBUTION OF MEDICATION POSSESSION RATIOS FOR ASTHMA CONTROLLER THERAPIES
PHARMACOECONOMIC ANALYSIS OF A NEW CONCEPT FOR SYMBICORT USE IN BRONCHIAL ASTHMA PATIENTS
DEVELOPMENT OF A COST-UTILITY MODEL FOR COMPARING GINA STEP 3 ASTHMA MEDICATIONS BASED ON UTILITY AND SAFETY DATA DERIVED FROM A LARGE HEAD-TO-HEAD TRIAL OF MONTELUKAST AND SALMETEROL
STATE TRANSITION MODELS FOR ESTIMATING TRANSITION PROBABILITIES IN MARKOV MODELS
THE RELATIONSHIP BETWEEN QUALITY OF LIFE AND WILLINGNESS TO PAY IN PATIENTS WITH ASTHMA IN KOREA
AN OBSERVATIONAL STUDY OF THE EFFECTIVENESS OF ROSUVASTATIN IN PATIENTS WITH DIABETES IN GENERAL PRACTICE ACROSS THE UNITED KINGDOM
EFFECTIVENESS OF MULTIPLE-MECHANISM ANTIHYPERTENSIVE MEDICATION
EFFECTIVENESS OF ROSUVASTATIN COMPARED TO OTHER STATINS FORTHE PREVENTION OF FATAL AND NON-FATAL CARDIOVASCULAR EVENTS IN CLINICAL PRACTICE— AN EPIDEMIOLOGICAL STUDY
META-ANALYSIS OF THE EFFICACY OF TELMISARTAN ON BLOOD PRESSURE IN PATIENTS WITH MILD TO MODERATE HYPERTENSION
EPROSARTAN VERSUS OTHERANGIOTENSIN-RECEPTOR BLOCKERS COMMONLY USED IN POLAND (IRBESARTAN, LOSARTAN, TELMISARTAN AND VALSARTAN) IN PATIENTS WITH HYPERTENSION-DIRECT ANALYSIS
ESTIMATING THE INCREMENTAL BENEFIT ON FINAL OUTCOMES OF ROSUVASTATIN 40 MG OVER 20 MG IN THE TREATMENT OF PATIENTS WITH HYPERCHOLESTEROLAEMIA BASED ON A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS
DIFFERENCES IN CHOLESTEROL LEVELS BETWEEN STATIN AND FIBRATE TREATED PATIENTS IN FRENCH, ITALIAN AND UNITED KINGDOM PRIMARY CARE
EPROSARTAN VERSUS OTHERANGIOTENSIN-RECEPTOR BLOCKERS COMMONLY USED IN POLAND IN PATIENTS WITH HYPERTENSION-INDIRECT ANALYSIS
DIFFERENT REDUCTIONS OF HOSPITALISATIONS FOR CARDIOVASCULAR EVENTS AMONG 92035 USERS OF STATINS IN A REAL LIFE SETTING
MULTIPLE REGRESSION ANALYSIS MODEL PREDICTED DIASTOLIC BLOOD PRESSURE
ASSOCIATION AND CONTROL OF MAIN CARDIOVASCULAR RISK FACTORS IN A SPANISH POPULATION SECTOR/ A CROSS-SECTIONAL STUDY
USING ADMINISTRATIVE DATA FOR QUALITY INDICATORS OF AMI HOSPITAL CARE IN HUNGARY
RISK OF MAJOR BLEEDING DURING CONCOMITANT USE OF ANTIBIOTIC DRUGS AND COUMARIN ANTICOAGULANTS
CHARACTERIZATION, RISK FACTORS, CLINICAL OUTCOMES, AND ECONOMIC CONSEQUENCES OF BLEEDING ASSOCIATED WITH CARDIAC SURGERY
IMPACT OF CHANGES IN REIMBURSEMENT SYSTEM ON THE BUDGET FROM THE PAYER'S AND PATIENT'S PERSPECTIVE
HEALTH INSURANCE COSTS OF STROKE HOSPITAL TREATMENTS IN HUNGARY/ 2003–2005
METABOLIC CONTROL AND COSTS OF PATIENTS WITH HIGH CARDIOVASCULAR RISK/ A CROSS SECTIONAL ASSESSMENT OF A HEALTH MANAGEMENT ORGANIZATION DATABASE
ECONOMIC BENEFIT OF IMPROVED PRESERVATION OF EXPLANTED ORGANS IN HEART TRANSPLANTATION
A MODEL-BASED ANALYSIS OF THE EFFECTS OF INTENSIFYING LIPID-ALTERING THERAPY ON DIRECT MEDICAL COSTS OF CORONARY HEART DISEASE EVENTS IN A SECONDARY PREVENTION POPULATION IN THE UNITED STATES
EVALUATING GENDER DIFFERENCES IN HEALTH CARE RESOURCE USE AND OUTCOMES AMONG ELDERLY PATIENTS WITH CONGESTIVE HEART FAILURE
COST-EFFECTIVENESS OF HYPERTENSION TREATMENT IN GREECE
COST EFFECTIVENESS ANALYSIS OF BOSENTAN FORTHE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN SOUTH KOREA
HOSPITAL COSTS FORTREATMENT OF ACUTE HEART FAILURE
COST EFFECTIVENESS OF THE CARDIOVASCULAR PREVENTION WITH RAMIPRIL AND/OR STATINS IN HIGH RISK POPULATION IN ITALY
COST-EFFECTIVENESS OF PREHOSPITAL VERSUS INHOSPITAL THROMBOLYSIS FOR ACUTE MYOCARDIAL INFARCTION
COST-EFFECTIVENESS OF HIGH DOSE ATORVASTATIN COMPARED TO STANDARD DOSE PRAVASTATIN IN SECONDARY PREVENTION
ECONOMIC EVALUATION OF NEBIVOLOL COMPARED WITH PLACEBO IN ELDERLY PATIENTS WITH HEART FAILURE -A MODEL BASED ANALYSIS ALONGSIDE THE SENIORS TRIAL
COST-EFFECTIVENESS ANALYSIS OF THROMBOPROPHYLACTIC STRATEGIES AFTER HIP FRACTURE REPAIR (HFR)
THE COST-EFFECTIVENESS ANALYSIS OF CORONARY ARTERY DISEASE DIAGNOSTIC PARAMETERS IN A CLINICAL LABORATORY SETTING
COST-EFFECTIVENESS OF CLOPIDOGREL IN MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION—A EUROPEAN MODEL BASED ON THE CLARITY AND COMMITTRIALS
LONG-TERM COST-EFFECTIVENESS OF RIMONABANT IN GERMANY
COST-EFFECTIVENESS OF IRBESARTAN IN THE TREATMENT OF PATIENTS WITH HYPERTENSION, TYPE-2 DIABETES AND RENAL DAMAGE IN MEXICO
RESOURCE USE AND TREATMENT COSTS FORACUTE DECOMPENSATED HEART FAILURE
COST-EFFECTIVENESS OF ATORVASTATIN PLUS AMLODIPINE VERSUS ATORVASTATIN PLUS ATENOLOL IN HYPERTENSIVE PATIENTS WITHOUT PREVIOUS CORONARY HEART DISEASE, NORMAL TO MILDLY ELEVATED CHOLESTEROL LEVELS AND AT LEAST 3 CARDIOVASCULAR RISK FACTORS
USE OF DRUG-ELUTING STENTS IN THE THERAPY AND PREVENTION OF RESTENOSIS
COST-EFFECTIVENESS OF THE MANAGEMENT OF FAMILIAL HYPERCHOLESTEROLAEMIA WITH A PREVENTIVE TREATMENT ATORVASTATIN-BASED
COST-EFFECTIVENESS OF ATORVASTATIN, ROSUVASTATIN, AND SIMVASTATIN IN REDUCING LDL-CHOLESTEROL TO MEET THE EUROPEAN TARGET LEVEL—BAYESIAN META-ANALYSIS AND SIMULATION
COST-EFFECTIVENESS OF ANGIOTENSIN RECEPTOR BLOCKERS IN PATIENTS WITH HYPERTENSION
COST UTILITY ANALYSIS OF CLOPIDOGREL IN ADDITION TO STANDARD CARE FOR ST-ELEVATED MYOCARDIAL INFARCTION
STUDY OF THE COST OF OUTPATIENT HYPERTENSION THERAPY IN BULGARIA
COSTS AND LENGTH OF STAY IN PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE
ANTICOAGULATION CONTROL IN DIFFERENT SETTINGS OF CARE
DIRECT COSTS ASSOCIATED WITH THE POTENTIAL COMPLICATIONS OF INCREASED CARDIOMETABOLIC RISK STATES
COST-EFFECTIVENESS ANALYSIS OF THE USE OFVISIPAQUE COMPARED TO OMNIPAQUE IN THE UNITED KINGDOM (UK)
COST-UTILITY ANALYSIS OF RIMONABANT IN THE MANAGEMENT OF OBESITY/OVERWEIGHT PATIENTS WITH CARDIOMETABOLIC RISK FACTORS IN HUNGARY
ECONOMIC EVALUATION OF 80 MG ATORVASTATIN COMPARED TO 20–40 MG SIMVASTATIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES
COST-EFFECTIVENESS OF ENDOVASCULAR REPAIR (EVAR) COMPARED WITH OPEN SURGERY REPAIR (OSR) FOR THE TREATMENT OF ABDOMINAL AORTIC ANEURYSM (AAA) IN ITALY
MAJOR BLEED RESOURCE USE AND COSTS FOR PATIENTS HOSPITALISED WITH ACUTE CORONARY SYNDROME IN FRANCE, ITALY, AND SPAIN
BUDGET IMPACT AND MEDICAL RESOURCES USED TO CONTROL BLEEDS IN PATIENTS HOSPITALIZED DUE TO ACUTE CORONARY SYNDROME (ACS)
COSTS OF MAJOR BLEEDS IN ACUTE CORONARY SYNDROME PATIENTS
ESTIMATING THE IMPACT OF MANDATORY SWITCH FROM ATORVASTATINTO SIMVASTATIN IN NORWAY
ATTITUDES AND BELIEFS OF PHYSICIANS ABOUT HYPERCHOLESTEROLEMIA IN SPAIN
STATIN USE AMONG PATIENTS WITH CONFIRMED CORONARY ARTERY DISEASE (CAD) OR RELATED RISK FACTORS
ATTAINMENT OF LDL CHOLESTEROL GOALS AMONG HIGH RISK PATIENTS WITH CARDIOVASCULAR DISEASE (CVD)
LIPID LOWERING AGENTS CONSUMPTION AND COSTS IN THE SLOVAK REPUBLIC
STATIN PRESCRIPTION PATTERNS IN A LOCAL HEALTH UNIT
UTILISATION OF DRUGS FOR TREATMENT OF CARDIOVASCULAR DISEASE WITHIN SLOVAKIA
COMPARISON OF REASONS BEHIND PHYSICIANS' ANTIHYPERTENSIVE THERAPY CHOICE IN THE UNITED STATES (US) AND EUROPE
ASSESSMENT OF THE USE OF ANGIOTENSIN RECEPTOR BLOCKERS IN THE EUROPEAN UNION PEDIATRIC POPULATION FOR TREATING ESSENTIAL HYPERTENSION
VARIATION OF OUTLIER PAYMENTS AMONG HOSPITALS
INDICATOR OF CARDIOVASCULAR MEDICINES USAGE IN PUBLIC PHARMACY CHAIN BELGRADE
PRIVATE PAYER EPISODE COSTS OF CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY VS. MYOCARDIAL PERFUSION IMAGING FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE
ESTIMATING A SOUTH AFRICAN PHARMACOECONOMIC THRESHOLD FOR PHARMACEUTICAL DECISION MAKING
CLINICAL AND ECONOMIC IMPACT OF DRUG-ELUTING STENT AND BARE METAL STENT IN HONG KONG-A SINGLE CETRE “REAL WORLD” EXPERIENCE
LIKELIHOOD OF INITIATING ANTILIPIDEMICS BY PATIENT SEX, RACE/ETHNICITY, AGE, AND COMORBIDITY
COMPARING QUALITY OF CARE
MANAGEMENT OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION WITH ST SEGMENT ELEVATION (STEMI) ACCORDING TO GUIDELINES IN SPAIN
CENTRALISED PAN-EUROPEAN SURVEY ON THE UNDER-TREATMENT OF HYPERCHOLESTEROLEMIA IN PATIENTS USING LIPID LOWERING DRUGS (CEPHEUS)
SIMPLE SENSITIVITY ANALYSIS TO ASSESS THE IMPACT OF ROUNDING OF BLOOD PRESSURE MEASUREMENTS ON ESTIMATES OF CONTROL RATES
MULTINOMIAL PROPENSITY SCORE ESTIMATORS AND MULTIVARIATE EXPLANATORYTECHNIQUES IN A REAL-LIFE ACUTE CORONARY HEART DISEASE STUDY—THE QALYS AND COSTS OF MEDICATION, PTCAAND CABG TREATMENT MODALITY ARE HIGHLY DEPENDENT ON THE METHODS USED
AN EVALUATION OF STATIN PERFORMANCE
EMPIRICAL EVALUATION OF THE PREDICTIVE PERFORMANCE OF CLASSIFICATION TOOLS IN CORONARY HEART DISEASE—P-COURSE, A NAIVE BAYESTOOL, OUTPERFORMS NOVEL LOGISTIC REGRESSION APPROACHES
ATOOL FOR MODELING MORTALITY DIFFERENCES IN PREDICTIVE SCREENING MODELS
A COMPARATIVE PHARMACOECONOMIC ANALYSIS OF STATINS IN RUSSIA
THE ANALYSIS OF HEALTH AND ECONOMIC BENEFITS AS THE CONSEQUENCE OF THE REALIZATION CARDIOVASCULAR SYSTEM DISEASES PREVENTION PROGRAMME AMONG THE CHILDREN AND YOUTH OF SCHOOL AGE IN POLAND
MEASUREMENT OF FRACTIONAL FLOW RESERVE IN PATIENTS WITH CORONARY ARTERY DISEASE TO GUIDE TREATMENT—RESULTS FROM A HEALTH TECHNOLOGY ASSESSMENT AND DECISION ANALYTIC MODEL
RESPONSE-SHIFT IN HEART DISEASE
MONITORING AND ASSESSING ADHERENCE TO STATINS THERAPY IN REAL PRACTICE USING ADMINISTRATIVE DATABASES
PERSISTENCE TO ANTILIPIDEMICS VARIES BY SEX, AGE, AND RACE/ETHNICITY
PERSISTENCE AND ADHERENCE TO HYPOLIPEMIC THERAPY IN REAL PRACTICE
PCV81
FACTORS INFLUENCING COMPLIANCE WITH COMBINATION ANTIHYPERTENSIVE PHARMACOTHERAPY IN A LARGE US DATABASE
ADHERENCE WITH ANTIHYPERTENSIVE DRUG TREATMENT
WHAT FACTORS AFFECT COMPLIANCE OF HYPERTENSIVE PATIENTS WITH THEIR TREATMENT? A QUALITATIVE STUDY
DOES A SINGLE PILL COMBINING AMLODIPINE AND ATORVASTATIN OFFER GREATER LONG-TERM ADHERENCE BENEFIT OVER LOW-COST GENERIC 2-PILL CALCIUM CHANNEL BLOCKER/STATIN REGIMENS?
THE IMPACT OF LOWERING SYSTOLIC BLOOD PRESSURE ON THE QUALITY OF LIFE OF HYPERTENSIVE PATIENTS IN GREECE
PCV87
QUALITY OF LIFE AS A PREDICTOR OF TREATMENT COMPLIANCE DURING ROUTINE HYPERTENSION MANAGEMENT
THE IMPACT OF COMMUNITY HEALTH WORKER INTERVENTION ON DISEASE MANAGEMENT AND QUALITY OF LIFE OF HIGH RISK POPULATION WITH CHRONIC DISEASE
INTEGRATION OF PATIENT-RATED OUTCOMES INTO CLINICAL ROUTINE IN INPATIENT AND OUTPATIENT CARDIAC REHABILITATION PROGRAMMES
HEALTH OUTCOMES IN PATIENTS WITH HYPERTENSION
ATTITUDES AND BELIEFS OF PATIENTS WITH HIGH CARDIOVASCULAR RISK, ABOUT HYPERCHOLESTEROLEMIA AND ITS TREATMENT IN SPAIN. THE PRACTICE STUDY
THE EFFECT OF EACH STAGE IN THE TRANSLATION METHODOLOGY FOR PRO MEASURES
EFFECTS OF COMORBID CONDITIONS AMONG THE OVERWEIGHT/OBESE ON WORK PRODUCTIVITY LOSS AND ACTIVITY IMPAIRMENT
SYSTEMATIC REVIEW OF THE SAFETY OF ANTIRETROVIRAL THERAPIES FOR REDUCING THE RISK OF MOTHER-TO-CHILD TRANSMISSION OF HIV INFECTION
THE NATIONAL HEALTH FOUND BUDGET IMPACT ANALYSIS OF INFLUENZA VACCINATION REIMBURSEMENT IN CHILDREN WITH MALIGNANCIES IN POLAND
AWORKSITE INFLUENZA VACCINATION PROGRAM IN RUSSIA
COST-BENEFIT ANALYSIS OF OSELTAMIVIR VERSUS NO ANTIVIRAL TREATMENT FROM THE EMPLOYER PERSPECTIVE
COST-EFFECTIVENESS OF TIGECYLINE IN THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN GERMANY
EPIDEMIOLOGIC AND ECONOMIC IMPACT OF ROUTINE VACCINATION OF INFANTS AGAINST ROTAVIRUS GASTROENTERITIS IN GERMANY
BURDEN OF PAEDIATRIC ROTAVIRUS GASTROENTERITIS AND POTENTIAL BENEFITS OF A UNIVERSAL VACCINATION PROGRAMME IN GERMANY
COST EFFECTIVENESS OF THE MF59-ADJUVANTED INFLUENZA VACCINE IN FRANCE
A COST-EFFECTIVENESS ANALYSIS OF A YEARLY FIBROSCAN® LIVER FIBROSIS ASSESSMENT COMPARED WITH A PERIODIC LIVER BIOPSY IN HEPATITIS C VIRUS (HCV) INFECTED INDIVIDUALS IN A FRENCH SETTING
COST-EFFECTIVENESS OF DIFFERENT PERTUSSIS VACCINATION STRATEGIES FORTHE PROTECTION OF YOUNG INFANTS
PIN 1 1
COST-EFFECTIVENESS OF LINEZOLID VS. VANCOMYCIN IN COMPLICATED SKIN AND SOFT-TISSUE INFECTION DUE TO SUSPECTED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN FRANCE
COST-EFFECTIVENESS OF LINEZOLID VS. VANCOMYCIN IN NOSOCOMIAL PNEUMONIA DUE TO SUSPECTED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN FRANCE
COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA SUSPECTED TO BE CAUSED BY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN SPAIN
COST-EFFECTIVENESS OF AUGMENTIN ES® FOR THE TREATMENT OF PAEDIATRIC ACUTE OTITIS MEDIA (AOM) IN POLAND
COST-EFFECTIVENESS OF AUGMENTIN ES®VS AZITHROMYCIN FOR THE TREATMENT OF PAEDIATRIC ACUTE OTITIS MEDIA (AOM) IN POLAND
ESTIMATING THE LONG-TERM HEALTH AND ECONOMIC IMPACT OF A PROPHYLACTIC CERVICAL CANCERVACCINE ON THE BURDEN OF CERVICAL DISEASE IN ITALY
COST-EFFECTIVENESS ANALYSIS OF OSELTAMIVIR FOR INFLUENZA IN JAPAN
A COST-EFFECTIVENESS ANALYSIS OF A PROPHYLACTIC CERVICAL CANCERVACCINE IN GERMANY
COST EFFECTIVENESS ANALYSIS OF BRIVUDINE COMPARED WITH ACICLOVIR FOR THE TREATMENT OF HERPES ZOSTER IN SPAIN
COST-EFFECTIVENESS OF INFLUENZA VACCINATION FOR HEALTHY ADULTS IN THE NETHERLANDS
A MULTINATIONAL PHARMACOECONOMIC EVALUATION OF DIRECT AND INDIRECT IMMUNITY CONFERRED BY THE SEVEN-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV7)
COST-EFFECTIVENESS ANALYSIS OF THE IMPLEMENTATION OF A QUADRIVALENT (6, 11, 16, 18 TYPES) HUMAN PAPILLOMAVIRUS VACCINE TO THE EXISTING BELGIAN CERVICAL CANCER SCREENING PROGRAMME
THE COST-EFFECTIVENESS OF A QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE (6, 11, 6, 18) IN NORWAY
A COST-EFFECTIVENESS STUDY OF A UNIVERSAL VACCINATION PROGRAM WITH THE 7-VALENT PNEUMOCOCCAL VACCINE (PCV-7) IN SWEDEN
THE COST-EFFECTIVENESS OF A QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE IN HUNGARY
THE COST-EFFECTIVENESS OF UNIVERSAL INFLUENZA VACCINATION FOR 50–64 YEAR-OLDS IN AUSTRALIA
A COST MINIMIZATION ANALYSIS COMPARING DIFFERENT ANTIBIOTIC REGIMENS USED IN TREATING PNEUMONIA IN HONG KONG
AZITHROMYCIN PLUS CEFTRIAXONE VERSUS LEVOFLOXACIN IN THE TREATMENT OF HOSPITALIZED PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA IN SPAIN.A COST-MINIMIZATION ANALYSIS
MULTI-CENTRE STUDY ON THE COSTS AND OUTCOMES OF ANTIBIOTIC TREATMENTS IN ITALY FOR COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI)
TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH SKIN AND SOFT TISSUE INFECTIONS IN BELGIUM
OUTCOMES AND COSTS OF HOSPITAL-ACQUIRED PNEUMONIA ASSOCIATED WITH PSEUDOMONAS OR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN A SAMPLE OF BELGIAN HOSPITALS
THE COST OF ZOSTERAND POST-HERPETIC NEURALGIA TREATMENT IN FRANCE
PIN34
MODELING THE LONG TERM CONSEQUENCES OF SUPPRESSING VIRAL REPLICATION IN CHRONIC HEPATITIS B
COST-UTILITY OF PEGINTERFERON-ALFA-2A (40 KD) IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B WITH AND WITHOUT THE “E” ANTIGEN IN BRAZIL
COST-UTILITY OF ALFAPEGINTERFERON-2A (40 KD) IN CO-INFECTED PATIENTS IN THE PRIVATE HEALTH CARE SYSTEM IN BRAZIL
AFFORDABILITY OF ANTIMALARIAL DRUGS IN BENIN CITY, NIGERIA
ECONOMIC EVALUATION OF A UNIVERSAL CHILDHOOD PNEUMOCOCCAL CONJUGATE VACCINATION STRATEGY IN IRELAND
PIN40
USE OF AN ADMINISTRATIVE DATABASE TO ESTIMATE THE ECONOMIC BURDEN OF FEBRILE NEUTROPENIA
EVALUATING THE CLINICAL EFFECTS AND THE COST-EFFECTIVENESS OF PROPHYLACTIC CERVICAL CANCERVACCINATION WITHIN AN ORGANISED POPULATION-BASED SCREENING SETTING—CASE FINLAND
ADAPTATION OF A HEALTH ECONOMIC MODEL OF THE NATURAL HISTORY OF HPV INFECTION AND CERVICAL CANCER IN A WELL FUNCTIONING POPULATION-BASED SCREENING SYSTEM—A MODEL CALIBRATION TO FINLAND
INCORPORATING PROBABILISTIC ATTRIBUTES IN A STATED-CHOICE RISK-BENEFIT SURVEY
HOW TO IMPROVE THE EXTERNAL VALIDITY AND EXTEND THE EXPIRATION DATE OF ECONOMIC EVALUATIONS
A CROSS-SECTIONAL VALIDATION OF THE MINI-HIV QUESTIONNAIRE
DEVELOPMENT AND PSYCHOMETRIC VALIDATION OF THEVACCINEES' PERCEPTION OF INJECTION (VAPI) QUESTIONNAIRE TO ASSESS SUBJECTS' ACCEPTANCE OF INFLUENZA VACCINATION
COMPARISON OF EMR DATA TO US NATIONAL DATA
A BAYESIAN ADAPTIVE DESIGN FOR EVALUATION OF THE GAP BETWEEN EFFICACY AND ERROR-ADJUSTED EFFECTIVENESS
FORMAL OBJECTIVE BAYESIAN METHODS IN COST-EFFECTIVENESS STUDIES
PROBABILISTIC SENSITIVITY ANALYSES IN HEALTH ECONOMIC MODELING STUDIES
USE OF A DIAGNOSIS-BASED RISK ADJUSTMENT MODEL TO ESTIMATE COSTS OF INDIGENT CARE IN A COMMUNITY AT MEDICAID REIMBURSEMENT RATES
THE OPERATIVE INTERVAL OF AN INCREMENTAL COST-EFFECTIVENESS RATIO
THE USE OF DISEASE TRANSMISSION MODELLING IN COST-EFFECTIVENESS ANALYSES
THE USE OF ADMNISTRATIVE DATABASE IN ITALY
PREVALENCE OF CONDITIONS IN THE US EMPLOYER INSURED POPULATION
SPATIAL INTERPOLATION
DEALING WITH COMPETING CAUSES OF DEATH, ILLNESS AND COSTS
DRUG ADMINISTRATION SERVICES
NONLINEAR SMOOTHING TO ASSESS PROBABILITIES OF ANTIBIOTIC-RESISTANT INFECTIONS IN THE COMUNITAT VALENCIANA (SPAIN)
ORDINAL OR CARDINAL? THE VAS STRIKES BACK
CONVERGENT, DISCRIMINANT, CONCURRENT VALIDITY AND RELIABILITY OF THE EQ-5D(CHILD)
SF-6D REFERENCE VALUES FOR SPANISH GENERAL POPULATION
ACCOUNTING FOR INITIAL HEALTH STATUS IN MEASURING THE BENEFITS OF HEALTH CARE TECHNOLOGIES
THE ROLE OF CONCEPTUAL MODELS, ENDPOINT MODELS, AND CONCEPTUAL FRAMEWORKS WHEN MAKING TREATMENT BENEFIT CLAIMS TO THE FDA
USE OF THE RELIABLE CHANGE INDEX TO EVALUATE CLINICAL SIGNIFICANCE IN HEART TRANSPLANTS
UTILITYWEIGHTED COMPAREDTO UNWEIGHTED EQ-5D AND HU13 SUMMARY SCORES
INFLUENCE OF “SOCIAL” AND “SCHOOL” LIFE DIMENSIONS ON CHILDREN'S QUALITY OF LIFE ASSESSED WITH EQ-5D (CHILD)
THE TURKISH WEIGHTING OF THE EUROQOL
VALIDITY OF THE SPANISH SF-6D TARIFFS AND EQ-5D COMPARING THE UTILITY VALUES OBTAINED IN FOUR DIFFERENT GROUPS OF PATIENTS
THE SELF-INJECTION ASSESSMENT QUESTIONNAIRE (SIAQ©)
USING DISCRETE CHOICE EXPERIMENT MODELLING TO ASSESS PREFERENCES FOR HEALTH CARE CHARACTERISTICS
UTILITY INDEX CALCULATION
VALIDATION OF THE CAT-HEALTH SYSTEM
EVALUATING THE EFFECTIVENESS OF SEARCH STRATEGIES FOR SYSTEMATIC REVIEWS
ESTIMATING THE BUDGET IMPACT OF NEWTECHNOLOGIES ADDED TO THE NATIONAL LIST OF HEALTH BENEFITS IN ISRAEL
ECONOMIC ADVANTAGES OF ONLINE DISCRETE EVENT SIMULATION TRAINING
EVALUATION OF THE PERSPECTIVE AND TYPE OF STUDIES IN ANIMAL HEALTH ECONOMICS
U.S. PHYSICIANS
GUIDELINES FOR ENSURING DEGREES OF VALIDITY IN HEALTH ECONOMIC MODELS
BIBLIOGRAPHIC REVIEW OF DISCRETE EVENTS SIMULATION STUDIES IN HEALTH TECHNOLOGY EVALUATION
DIRECT HEALTH COSTS OF TREATING PATIENTS WITH FIBROMYALGIA IN PRIMARY CARE SETTINGS (PCS) UNDER ROUTINE MEDICAL PRACTICE
PATIENT-REPORTED-OUTCOMES (PRO) AS A DRIVEN OF DIRECT HEALTH COSTS IN SUBJECTS WITH FIBROMYALGIA
IMPACT OF OBESITY UPON COSTS AND ANTIPSYCHOTIC DRUG USE IN THE ADULT POPULATION SEEN IN SPANISH PRIMARY CARE CENTERS
REDUCING GLOBAL CARDIOMETABOLIC RISK IN OVERWEIGHT OR OBESE INDIVIDUALS WITH DYSLIPIDEMIA
A PROBABILISTIC BAYESIAN MARKOV MODEL IN WINBUGS FOR THE ECONOMIC EVALUATION OF THE TREATMENT WITH ORLISTAT OF ITALIAN OBESE PATIENTS
GEMCAS MODEL—A DECISION ANALYTIC MODEL ASSESSING THE COST-EFFECTIVENESS OF TREATMENTS FOR OBESITY AND ASSOCIATED CARDIOVASCULAR RISK FACTORS
QUANTIFYING THE QUALITY OF ECONOMIC EVALUATIONS OF OBESITY INTERVENTIONS
INCIDENCE OF ACUTE PAIN IN TURKEY
A COST MINIMIZATION ANALYSIS OF IV BOLUS VERSUS IV INFUSION DICLOFENAC IN POST-OPERATIVE PAIN
EXPECTED COST AND COST CONSIDERATIONS ASSOCIATED WITH OPIOID ROTATION FOR CHRONIC NON-CANCER PAIN
HEALTH, NON-HEALTH RESOURCES UTILIZATION AND COSTS OF TREATING REFRACTORY PAINFUL RADICULOPATHY IN PRIMARY CARE SETTING (PCS) UNDER ROUTINE MEDICAL PRACTICE IN SPAIN
LONGITUDINAL HEALTH AND NON-HEALTH RESOURCES UTILIZATION AND DERIVED COSTS OF TREATING REFRACTORY PAINFUL RADICULOPATHY IN PRIMARY CARE SETTING (PCS)
HEALTH, NON-HEALTH RESOURCES UTILIZATION AND COSTS OF TREATING REFRACTORY PERIPHERAL NEUROPATHIC PAIN (NEP) IN PRIMARY CARE SETTING (PCS) UNDER ROUTINE MEDICAL PRACTICE IN SPAIN
RESOURCE UTILIZATION DUE TO BREAKTHROUGH PAIN
CHRONIC PAIN TREATMENT WITH OPIOIDS
PERCEPTION OF BREAKTHROUGH PAIN IN PATIENTS WITH CHRONIC PAINFUL CONDITIONS
LINGUISTIC ADAPTATION INTO SPANISH AND PSYCHOMETRIC VALIDATION OF THE NEUROPATHIC PAIN SCREENING QUESTIONNAIRE
ELICITING UTILITY SCORES FOR HEALTH STATES ASSOCIATED WITH SEVERE CHRONIC PAIN
TURKISH MCGILL PAIN QUESTIONNAIRE
IMPACT OF SECONDARY PROPHYLACTIC USE OF TACROLIMUS 0.1% OINTMENT ON QUALITY-OF-LIFE, TREATMENT OUTCOMES AND COSTS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
PSOBEST. EFFECTIVENESS AND SAFETY OF LONG-TERM SYSTEMIC PSORIASIS-THERAPY
PSK3
COST COMPARISON BETWEEN TWO ANTI-TUMOR NECROSIS FACTOR (ANTI-TNF) THERAPIES IN PATIENTS WITH PSORIASIS USING AVERAGE SALES PRICE
MANAGEMENT AND COST OF GENITAL WARTS IN ITALY
IMPACT OF PSORIASIS DISEASE ON ANNUAL TOTAL HEALTH CARE COSTS AND RESOURCE UTILIZATION AMONG MEDICAID RECIPIENTS
EVALUATION OF THE ASSOCIATION BETWEEN PSORIASIS SEVERITY AND HOSPITAL RESOURCE USE IN THE UNITED KINGDOM
ASSESSMENT OF INVOLVED BODY SURFACE AREA (BSA) IN PSORIASIS PATIENTS.VALIDATION OF SOFTWARE ASSISTED DIAGNOSIS BSA FOR THE MANAGEMENT OF PSORIASIS
PRIOR AUTHORIZATION FOR TOPICAL PSORIASIS TREATMENTS
QUANTITATIVE ASSESSMENT OF PATIENT-DEFINED BENEFIT IN DERMATOLOGY
EVALUATION OF THE ASSOCIATION BETWEEN EQ5D UTILITY AND DERMATOLOGY LIFE QUALITY INDEX (DLQI) SCORE IN PATIENTS WITH PSORIASIS
PATIENT REPORTED OUTCOMES IN PSORIASIS
PSYCHOMETRIC VALIDATION OF THE OILY SKIN SELF ASSESSMENT SCALE (OSSAS) AND THE OILY SKIN IMPACT SCALE (OSIS)
COST-EFFECTIVENESS ANALYSIS OF CHAMPIX® (VARENICLINE) IN SMOKING CESSATION TREATMENT IN SPAIN
A COST—EFFECTIVENESS ANALYSIS OF A COMMUNITY PHARMACIST BASED SMOKING CESSATION PROGRAM IN THAILAND
AN EVALUATION OF THE COST-EFFECTIVENESS OF AN EXTENDED COURSE OF VARENICLINE IN PREVENTING SMOKERS WHO HAVE QUIT FROM RELAPSING
HEALTH ECONOMIC MODEL OF SMOKING CESSATION TREATMENT WITH VARENICLINE IN GERMANY
USE OF THE INSULIN TREATMENT SATISFACTION QUESTIONNAIRE (ITSQ)ANDTHE ENVIRONMENTAL TOBACCO SMOKE QUESTIONNAIRE (ETS-Q) IN AN INTERNATIONAL STUDY
REAL WORLD USAGE PATTERNS OF OVER-THE-COUNTER NICOTINE PATCHES
COST-EFFECTIVENESS OF STAPLED HAEMORRHOIDOPEXY (PPH) COMPARED WITH MILLIGAN-MORGAN TECHNIQUE MM IN PATIENTS IN WHOM SURGICAL INTERVENTION IS CONSIDERED APPROPRIATE FORTHETREATMENT OF PROLAPSED INTERNAL HAEMORRHOIDS IN UNITED KINGDOM
PSU2/ES4
THE EFFECTS OF LAPAROSCOPIC SURGERY AND NOSOCOMIAL INFECTIONS ON THE COST OF CARE
RETROSPECTIVE STUDY OF COMPLICATIONS AND RESOURCE USE IN ENDOVASCULAR MANAGEMENT OF AAA
SYSTEMATIC REVIEW OF PATIENT REPORTED OUTCOMES FOLLOWING INTRADISCAL ELECTROTHERMAL THERAPY (IDET) OR SPINAL FUSION FOR DISCOGENIC LOW BACK PAIN
PHARMACOECONOMIC EVALUATION IN THE IRISH HEALTH CARE SETTING